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Abstract 
 
The fundamental questions behind this thesis are: Can we save money in the 
surgical treatment of osteoarthritis in the knee? And if so, what areas should we be 
looking at and how can we do it?  
 
Osteoarthritis represents a considerable cost to the UK economy. A review of the 
economic costs of osteoarthritis was performed as part of this thesis. While 
estimates of economic costs can be made, one conclusion from the studies does 
seem clear: that these costs are very significant and are continuing to rise. Based on 
data from the UK National Joint Registry (NJR), there has been a substantial 
increase in the number, and hence the costs of knee replacements to the NHS over 
the last 10 years.  
 
At the time this thesis started in 2011, the NHS had also begun a previously 
unprecedented slowdown. This resulted in a significant funding gap. The estimated 
shortfall in funding, in order for the NHS to cope with events such as increasing 
numbers of aging population or the cost of increases in new medical technology, has 
been calculated as £20 billion by 2014, with an additional, further funding shortfall of 
an estimated £30 billion by 2020. As a result, an intensive programme targeting  
productivity improvement was instituted with a view to solving this deficit through 
improvements in efficiency.  
 
It is well known amongst accounting circles that what cannot be accurately 
measured, cannot be controlled. One of the aims of this thesis was to improve on the 
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existing costing methodology utilised for knee replacement surgery. In order to better 
control costs, and understand where the cost drivers in such surgery lay, the patient 
pathway for total knee replacement was prospectively mapped utilising a Time driven 
Activity based costing model. Timings were prospectively collected as the patient 
was followed through the TKR pathway. All costs for the patient pathway from 
admission through to discharge, as well as pre-operative assessment clinic and joint 
school, were analysed. The major cost drivers involved in the Total Knee 
Replacement pathway were identified as a result of this study. This data was then 
subsequently utilised at our institution to implement further cost reduction strategies 
in knee replacement surgery. 
 
Litigation in healthcare has also dramatically increased over the last 10 years. The 
outstanding liability of clinical negligence claims, according to data from the National 
Health Service Litigation Authority (NHSLA), exceeded £1.3 billion by 2011. The 
NHSLA also reported a year-on-year increase in such claims. A review of NHSLA 
database was performed as part of this thesis. All cases involving adverse events 
occurring as a result from surgery to the knee were examined, to determine the costs 
of these adverse events, to analyse trends and predict future costs. A significant 
number of events involving technical errors were identified as part of this review. In 
addition to the cost implications, this represents potentially preventable events, and 
may represent an issue with training and/or patient safety.  
 
A study analysing the clinical relevance and costs of repeating x-rays for knee 
osteoarthritis was also undertaken. Only a small proportion of patients referred for 
knee radiographs have weight-bearing films, with a significant number of hospitals in 
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London do not routinely perform weight-bearing radiographs to investigate suspected 
knee osteoarthritis. The potential delay in diagnosis, referral or treatment of these 
patients, in addition cost burden to the NHS was examined. 
The principles of Time Driven Activity based costing was successfully applied to a 
small cohort of Total Knee Replacement patients in our study. There remains the 
potential for larger studies with more heterogeneous patient groups to better inform 
policy makers attempting to benchmark treatment costs more accurately.  
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Chapter 1 
The Global economic costs of osteoarthritis1 
 
1.1 Introduction 
Musculoskeletal diseases remain one of the most common causes for severe long 
term pain and disability. The increasing significance of musculoskeletal disorders 
has prompted the United Nations, the World Health Organization (WHO) and 37 
countries to spearhead a campaign to recognise and address the burden of 
musculoskeletal disorders such as arthritis, proclaiming it to be the Bone and Joint 
Decade (2000-2010) [1], and to advance understanding and treatment of 
musculoskeletal disorders through prevention, education and research. 
 
Within the envelope of musculoskeletal disorders, Osteoarthritis represents a 
complex musculoskeletal disorder with multiple genetic, constitutional and 
biomechanical risk factors. It represents the most common form of joint disease and 
disability in older people and ranks amongst the top 5 causes of disability[2].  
 
Old age remains the greatest risk factor for the development of osteoarthritis, 
although it is not an inevitable consequence of growing old [3]. There remains a 
growing concern however, that with the increasing numbers of the UK’s population 
                                                          
1 This chapter is based, substantially or wholly on an article which published in Arthritis Journal: 
The Global Economic Cost of Osteoarthritis: How the UK Compares. Chen A1, Gupte C, Akhtar 
K, Smith P, Cobb J.;2012:698709. doi: 10.1155/2012/698709. Epub 2012 Oct 2 
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over the age of 65, the economic burden of the treatment of osteoarthritis will 
likewise increase. Currently, the UK has an estimated 10 million people over the age 
of 65. In 20 years, this amount is expected to increase by 5 ½ million and nearly 
double (to 19 million) by 2050 [4]. 
 
1.2 Types of Economic Costs 
The economic costs of osteoarthritis can be broken down into direct costs and 
indirect costs. Direct costs represent the pharmacological/non-pharmacological 
treatments, including surgery, as well as use of hospital resources and management 
of complications arising from the treatment of osteoarthritis. Indirect costs represent 
loss of time from work, decreased productivity because of pain, care-giver time, 
premature mortality and disability compensation/benefits. These costs are 
summarised in Table 1, below. 
 
A third category sometimes considered is that of intangible costs. These are defined 
as the pain and suffering experienced by the patient as a result of the disease; the 
reduction in the patient’s quality of life. They remain an area of controversy, with only 
a few studies making the attempt to estimate them [5].     
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Table 1 
 
Direct Costs Indirect Costs  
 
Intangible Costs 
Costs of Surgery Loss of Productivity  Pain and Suffering 
Hospital resources Absenteeism  Decreased Quality 
of Life 
Care-giver Time Premature Mortality Potential 
Depression/Anxiety  
Pharmacological and 
Non-Pharmacological Treatment 
Disability 
Payments/Benefits 
 
Costs of Side effects from 
Treatments 
  
Research   
 
 
1.3  Aims of the review 
The aim of this review is determine the extent of the costs involved in the treatment 
of osteoarthritis in the UK and abroad; to determine the scope of the problem, and 
also whether such costs are rising or diminishing.  
 
The review examines all relevant literature on the economic costs of Osteoarthritis in 
the UK, and aims to see what comparisons can be made regarding such costs 
between the UK and other countries in North America, Europe and Asia. 
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1.4 Materials and Methods 
 
A comprehensive review of the literature was performed using a computerised 
bibliographical search of MEDLINE databases from 1946 to 31st Dec 2011. English 
language articles were reviewed that contained the words “economic cost”,  “direct 
cost” or “indirect cost” in combination with “osteoarthritis” in either their title or 
abstract.  
 
To expand the review beyond only published studies, an internet search was made 
for publications from the UK Department of Health, the National Institute for Clinical 
Excellence, the UK National Joint Registry, Hospital Episode Statistics as well as 
charities Arthritis Research (UK) and Arthritis Care and all publications were 
reviewed for information on costs for osteoarthritis.  Further internet searches were 
made for publications from the British Orthopaedic Association, the Royal College of 
Surgeons, the Royal College of Physicians and the Royal College of General 
Practitioners. Publications from American Association of Orthopaedic Surgeons and 
other regional orthopaedic associations in Europe and Asia were also reviewed. 
 
 
1.5 Results 
1.5.1 What do we know about OA costs in North America? 
 
Studies on prevalence of osteoarthritis in the United States have shown that 
osteoarthritis affects 13.9% of adults aged 25 and older, and 33.6% of those over the 
23 
 
age of 65, with an approximate 27 million Americans of all ages suffering from 
disease [6].                                                                                                    
 
Much of the data available on osteoarthritis in the United States is derived from 
studies conducted in the 1960’ and 1970’s. The Framingham study [7] represented 
one of the early studies to associate increasing age with worsening knee arthritis. 
This study, which began in 1948, was initially designed to look at cardiovascular risk 
factors in a representative sample of people in the adult population of Framingham, 
Massachusetts. The study’s patients were examined every 2 years since inception. 
This same cohort of patients was used by Felson et al to look at the prevalence of 
knee osteoarthritis approximately 36 years after the start of the study. The age of the 
patients in the study ranged from 63 to 94, and a total of 1805 patients were studied. 
The study confirmed that radiographic evidence of OA increased with age, with a 
higher prevalence of OA changes in women, as well as a significantly higher 
proportion of women with symptomatic OA.  
 
Lethbridge et al [8] examined discharge data from the National Hospital Discharge 
Survey and concluded that Osteoarthritis accounts for 55% of all arthritis related 
hospital admissions, with 409 000 such admissions in 1997. The annual cost of knee 
and hip replacements in 1997 was estimated at $7.9 billion (£4.7 billion) [8]. Less 
than 10 years later in 2004, the number of hospital admissions had risen to 632 000 
and the annual total cost of joint replacements rose to $22.6 billion (£13.8 billion) [9].  
 
Buckwater et al [10] used data drawn from national data sets collected by the US 
Bureau of Labor Statistics, the US National Center for Health Statistics, as well as 
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existing cost estimates for arthritis in the literature, used proportional attributable risk 
models and the human capital method to break down costs into direct and indirect 
costs. From this study, an estimated $3.4-$13.2 billion (£2 billion -£8 billion) is spent 
annually on job-related OA costs in the USA. Meanwhile, Kotlarz et al, in 2010, using 
evidence from the national health survey data from 1996-2005, looked at 
absenteeism as a result of osteoarthritis. This study, estimated the indirect cost of 
the absenteeism to be approximately US$10.3 billion [11]. The study also confirmed 
that the costs for women were larger (US$ 5.5 billion compared to US$4.8 billion), 
and that absenteeism was less in subjects with lower education and those in minority 
groups. 
 
A survey done by Gupta et al, in Ontario, Canada in 2005, estimated that the indirect 
costs incurred by a patient aged over 55 with hip or knee arthritis may be much 
higher than previously estimated when compared to direct costs ($12 990 or £ 8183 
annually for the former, and $2300 or £1449 for the latter) [12]. Indirect costs were 
incurred mostly for time lost from employment and for unpaid informal caregivers, 
with caregiver time accounting for 40% of indirect costs. It should be noted that the 
authors in this study based the costs on the monthly wage for a professional 
homemaker or housekeeper as caregiver occupation was unknown. This averaged 
at US$ 1278 (£824) per month, which may explain the relatively higher costs 
reported.  
 
March et al (1997) looked at the global cost of osteoarthritis and found the cost of 
osteoarthritis in the USA, Canada, UK, France and Australia to account for between 
1-2.5% of the Gross National Product (GNP) for those countries [13].  
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1.5.2 How do recent studies in Europe compare? 
 
Loza et al, in their Spanish study examined the burden of knee and hip osteoarthritis, 
examined 1071 patients across all the provinces of Spain [14] . The average annual 
cost for OA was estimated at €1502 (£1260), with direct costs representing 86% 
(£1084) of the total cost. Indirect costs were much lower (14% or £176) and mainly 
involved domestic help. 
 
In contrast to this, The COART Study [15] in France attempted to estimate the 
overall financial cost of osteoarthritis to the country. The study concluded that 
osteoarthritis remained a major public burden, with direct costs in 2002 exceeding 
1.6 billion Euros, about 1.7% of the expenses of the French Health system. Over 13 
million visits were made to physicians for osteoarthritis. Medication costs were 570 
million euros and inpatient treatment amounted to 820 million Euros. During the 
period of the study, 80 000 total hip replacements and 38 000 total knee 
replacements were performed per year, at a cost of €5600 per THR and €4500 per 
TKR. The study compared the costs to a previous study by Levy [16] in 1993 and 
found that the prevalence of the disease had risen by 54%, and the direct medical 
costs by 156%.  
 
In Italy, Leardini et al examined the economics of osteoarthritis of the knee in 2004. 
They used a bottom-up method and reviewed patients across 29 medical institutes. 
They concluded that the direct costs came to €934 (£785) and indirect costs €1236 
(£1039) per patient per year [17]. 
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1.5.3 Is the Situation different in Asia? 
 
There have been fewer studies with regard to economic costs of osteoarthritis in 
India, China or South-east Asia compared with countries in the western hemisphere.  
 
In contrast to the Western literature, Woo et al, in their Hong Kong [18] study 
estimated that the cost of osteoarthritis accounted for 0.28% of the GNP of Hong 
Kong, between HK $3.2-$3.9 billion (£253 million - £308 million). The direct costs 
ranged from HK $4860-$11180 (£384 - £883) and indirect costs HK$3300-$6640 
(£261-£525) per person annually. 
 
Xie et al assessed indirect costs in Singapore for OA and noted that there were 
estimated at between US$1000-1200 (£610-£730), around 2.8% and 3.3% of the 
annual household income [5]. The authors here acknowledged that these costs likely 
represented the lower end of the scale, as costs such as loss of productivity of 
caregivers were not estimated. The study was also one of the few that attempted to 
address and estimate intangible costs using the willingness to pay (WTP) method. In 
economics, this model represents the maximum amount a person would be willing to 
pay, sacrifice or exchange in order to avoid something undesired, in this case, the 
pain and suffering associated with osteoarthritis. The authors here estimated the 
intangible costs at US$ 1200 (£775) per year define intangible costs.  
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Table 2: Summary of Literature review of OA costs worldwide 
Author Year of 
study 
Country Cost 
Studied 
Individual cost 
per annum 
(2010 £) 
per OA patient 
Population 
Cost per annum 
(2010 £) 
McClean 
et al 
 
Lanes et 
al 
 
Buckwater 
et al 
 
1993 
 
 
1994 
 
2000 
USA 
 
 
USA 
 
USA 
Direct 
Costs 
 
 
Direct 
Costs 
 
Indirect 
Costs 
 
£1526 
 
 
£496 
 
N/A 
US $548 million 
 
 
N/A 
 
£2 billion - £8 
billion 
 
Kotlartz et 
al 
 
2005 USA Indirect 
Costs 
 
£355 £7.25 billion 
Maetzel et 
al 
 
2000 Canada Direct 
Costs 
Indirect 
Costs 
 
£3162 
£1407 
N/A 
N/A 
Gupta et 
al 
2002 Canada Direct 
Costs 
£1768 
£9986 
N/A 
N/A 
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Indirect 
Costs 
 
Loza et al 2003 Spain Direct 
Costs 
Indirect 
Costs 
 
£1292 
£209 
£4.04 billion 
£654 million 
Le Pen et 
al 
 
2003 France Direct 
Costs 
 
£316 £1.58 billion 
Leardini et 
al 
2001 Italy Direct 
Costs 
Indirect 
Costs 
 
£ 981 
£1299 
N/A 
N/A 
Woo et al 2001 
 
Hong 
Kong 
Direct 
Costs 
Indirect 
Costs 
 
£6561 
£620 
£323 million 
(combined cost) 
Xie et al 2005 Singapore Indirect 
Costs 
 
£610-£730 N/A 
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1.5.4 What do we know about the economic cost of OA in the UK? 
 
The Prevalence of OA 
 
The Arthritis Research Council (UK) estimated in 2002 that at least 4.4 million 
patients in the UK have x-ray evidence of moderate to severe osteoarthritis in their 
hands, while 550 000 have similar evidence of osteoarthritis in their knees and 210 
000 have evidence of this in their hips [19]. 
 
Pye et al, in 2004, showed that almost 8.5 million people in the UK have x-ray 
evidence of osteoarthritis in their spine, with back pain the most frequent symptom  
(18). While predominantly a disease of the elderly, an estimated 6% of adults aged 30 
and above have both knee pain and radiographic changes of osteoarthritis [20]. 
 
The Royal College of General Practitioners estimated in 2006 that in the UK over 1 
million adults consult their GP each year with symptoms of osteoarthritis [21]. 
Another study in 2007 showed that consultations for osteoarthritis account for 15% of 
all musculoskeletal consultations in those aged 45 and over, rising to 25% in those 
aged 75 and over (21). The cost per consultation is estimated at £36 for a 12 minute 
consultation [22]. 
 
During the year from 1999-2000, there were 114,500 hospital admissions related to 
osteoarthritis in the UK [19]. The latest HES data (2010-2011) have shown a 
significant increase in hospital admissions – for hip and knee arthritis alone, the 
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combined figure was 181,350 admissions [23]. When the diagnoses for polyarthritis 
and ‘other arthritis’ – but not rheumatoid conditions or crystal arthropathy- are 
included, the total number of admissions in 2010/11 was 207,041, representing an 
80% increase compared with figures 10 years ago. 
 
Surprisingly, there are no published studies in the literature with regard to direct or 
indirect costs of osteoarthritis in the UK. Data, however, is instead only available 
from a variety of other sources.  
 
 
1.5.5 What information is available from other sources about costs in the
 UK? 
 
Direct Costs 
The National Institute of Clinical Excellence (NICE) recently published a costing 
report in 2008 with regard to implementing the guidelines for treatment of 
osteoarthritis [24]. In the report, NICE estimated the prevalence of osteoarthritis in 
the UK to be a total of 2.8 million patients, based on symptomatic diagnosis in 
patients aged over 45. The analysis covered the management of osteoarthritis in all 
such patients. 
 
The cost of topical and oral Non-Steroidal Anti-inflammatories (NSAIDs) was 
estimated using prescribing data from 2005/06 [24]. An estimated 167 000 people 
who had a diagnosis of osteoarthritis was found to have been prescribed topical 
NSAIDs, and it was estimated that 50% (1. 4 million patients) of patients with 
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osteoarthritis was prescribed oral NSAIDs. The annual cost in 2005/06 of prescribing 
topical NSAIDs was £8.5 million and £25 million for oral NSAIDs. The cost for topical 
NSAID prescriptions was anticipated to double, and the cost of oral treatment 
reduced by 10%, if the new guidelines are followed. Adjusting for inflation, in 2010 
prices, this would equate to £19.2 million and £25.65 million respectively. 
 
The cost of iatrogenic events related to NSAID use is also substantial. NSAID related 
iatrogenic events have been estimated to be an estimated £32-£70 per patient 
prescribed an NSAID in the UK. This equates to a total cost of £166 - £367 million 
per year (£210.9-£466.2 million at 2010 prices) [25] 
 
The cost of Proton Pump Inhibitor (PPIs) prescription for use with NSAID treatment 
was £26 000 in 2005/06 but expected to rise significantly to £10.5 million (£11.6 
million in 2010) with implementation of the new guidance.   
 
The 2005/06 Hospital Episode statistics stated that the total number of people aged 
45 and over who received arthroscopic lavage and debridement for knee 
osteoarthritis was approximately 20 000. The national tariff for arthroscopies set by 
the Health Resource Group in 2008/09 was £1264, resulting in a cost £25 million for 
such treatment. It should be noted that NICE expected the cost of this to fall 
dramatically (by 19000 patients), with guidelines restricting the use of arthroscopic 
treatment to patients with ‘mechanical’ symptoms such as locking or giving way. The 
new cost for arthroscopic treatment of osteoarthritis is calculated (£1264 x 1000 
patients) at £1.26 million (£1.3 million in 2010).  
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1.5.6 Economics of Joint replacement 
 
According to the 8th Annual report of the NJR, published September 2011 [24], a 
total 76,759 primary total hip replacements and were performed in 2010, a 6% 
increase from 2009. The revision ‘burden’ was approximately 11% with 7852 hips 
revised in 2010. A total of 81,979 knee replacements were done in 2010, 
representing an increase of 5.7% when compared with 2009. The revision ‘burden’ 
here was less, at just over 6% requiring revision in 2010. The proportion of Total 
knee replacements to uni-condylar knee replacements and patella-femoral knee 
replacements have remained largely the same for the last few years.  
 
While there are other causes for joint replacement surgery, osteoarthritis remains the 
most frequent cause for hip replacement [93% of primary hip replacements in 2010] 
and knee replacement [97% of primary knee replacements in 2010].  
 
The costs of hip and knee replacements vary considerably from trust to trust in the 
UK with no set national price for implants, and the cost also being significantly 
dependant on length of hospital stay. The tariff reimbursement paid to the trust in 
one study [26] in 2005/06 was £6000 for a primary total hip replacement and £6800 
for a primary total knee replacement. The national tariff for 2010 was set at £5552 for 
an uncomplicated total hip replacement and £5198 for a similar total knee 
replacement. This leads to an estimated cost of £426 million for total hip 
replacements and £426 million for primary total knee replacements, giving a 
combined total cost for primary hip and knee replacements of £852 million in 2010. 
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This represents a substantial increase in costs over the last 10 years, when 
compared to the expenditure of £405 million in 2000 for 44 000 hip and 35 000 knee 
replacements [19].  Even adjusting for inflation, this cost would only be £514 million 
in 2010, representing a 66% increase in the last 10 years. 
 
The latest NJR report (12th Annual report) published in 2015 notes 83,125 primary 
total hip replacements were performed and 91,955 total knee replacements were 
performed in 2014. Osteoarthritis was stated to be a cause for the procedure in 93% 
of the hip replacements. For the knee replacements, it was the sole stated reason for 
the procedure in 96% of cases. These figures represent a further 8.2% and a further 
12.2% increase in the number of knee replacements since 2010. [27] 
 
Table 3: Summary of Direct costs of OA in the UK 
 
 
1.5.7 Indirect Costs 
Osteoarthritis has a significant negative impact on the UK economy with an 
estimated total cost of 1% of GNP [28]. The department of Work and Pensions 
estimate that 36 million work days were lost because of osteoarthritis in 2002, 
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resulting in a loss of economic production over £3.2 billion; while at the same time, 
£43 million was spent on community services and £215 million spent on social 
services for osteoarthritis [29].  
 
Arthritis remains the most common condition for people to receive the Disability 
Living Allowance [DLA], with £2.41 billion paid to people claiming incapacity benefit 
due to arthritis and related conditions in 2001 [29]. More than half a million people 
receive the DLA because of arthritis, more than the total for heart disease, stroke, 
chest disease and cancer combined 16. Only around 1 in 200 of those on benefit later 
returns to work [30].  
 
The most recent review of disability costs in the UK was done by Dame Carol Black 
[31] in her review of the health of the working age population. Unfortunately, the 
review did not offer a breakdown of the components in musculoskeletal disability 
costs and so, despite the report, the exact contribution of OA to such costs in the UK 
remains unknown. 
 
1.6 Discussion  
 
The review demonstrates that osteoarthritis represents an increasing economic 
burden to all countries, both from direct costs and indirect costs. Economic data on 
osteoarthritis has been made difficult because of problems defining the prevalence 
and incidence of the disease. There is only sparse literature available regarding 
economic costs in the east, but what is more surprising is the lack of clear costing 
studies in the west, especially in the UK.  
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Direct costs may vary from country to country, which is to be expected given their 
different health systems, and even between institutions in a country. Significant 
variability is seen from these studies, making direct comparison difficult. 
Compounding the problem is the fact that the methodology used in estimating these 
costs can vary from study to study, and not all studies give a clear breakdown of the 
calculation of the direct costs involved [32].  
 
Furthermore, in the studies provide a breakdown of the direct costs, few include the 
cost of alternative therapies in the treatment of osteoarthritis. There is evidence that 
nearly half (47%) of older patients in one American study [33] used an alternative 
type of therapy and these costs are considerable (US$ 1127 or £723 per annum). 
Hence, the true economic burden of direct costs in osteoarthritis is likely to be 
significantly higher than most of these studies indicate. 
 
The significant variability in indirect costs from these studies is also a concern. This 
is likely to be due to the lack of a standardized method to estimate indirect costs – 
unfortunately, there remains at present no good evidence to support one preferred 
method over the others [32]. Most studies conclude that indirect costs, however, 
represent a largely underestimated economic burden to country, and as such, these 
estimates may just be the tip of the iceberg. 
 
The orthopaedic workload is significant and rising, as can be seen from the 
increasing numbers of joint replacements performed, according to data from the 
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NJR. In particular, the numbers of total knee replacement performed in the UK have 
increased more than hip replacements, in the last 5 years.  
 
The NHS budget in 2010/11 was £121 billion [34].  It has been estimated that around 
£10 billion is spent on musculoskeletal disorders and around 25% of the surgical 
interventions within the NHS are for the treatment of musculoskeletal disease [35].  
 
 
1.7 Conclusion 
 
Our review of the literature suggests that while there are a large number of studies 
on economic costs of osteoarthritis, from multiple countries, the information available 
in the literature remains patchy and difficult to interpret. Some studies focus on the 
macroeconomic angle, looking at costs at a national scale or costs per capita while 
others focus on costs from the view of the individual patient with OA. Other studies 
are only specific for arthritis of a single joint. Even with studies compatible from this 
point of view, the varied methodology and lack of standardization of costing make it 
impossible to accurately compare economic costs, whether direct or indirect.  
 
The continuing lack of published data regarding direct and indirect OA costs in the 
UK, especially from the patient perspective, shows that more research into this area 
is vital. This will allow us fully appreciate the healthcare burden of OA in the UK, as 
well as to make more accurate financial planning for the provision for healthcare 
services for the treatment of OA in the subsequent decade to come. 
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Despite such difficulties, one conclusion does seem clear from these studies: that 
such costs are very substantial and are continuing to rise. The demand for 
orthopaedic interventions in the treatment of osteoarthritis is also rising.  
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Chapter 2 
The Political and Economic climate 
2.1 Introduction 
At the time this thesis started in 2011, the NHS had started an unprecedented 
slowdown, which began in 2010, following a period of significant growth. This 
slowdown resulted in a significant funding deficit and the NHS therefore, required to 
begin an aggressive programme of productivity improvement and efficiency savings 
in order to meet this shortfall. 
 
Source for Figure 1: The King’s Fund  
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Data from the King’s fund report [36] showed that between 1997 and 2010, the NHS 
experienced annual increases for its budget, in real terms, of 5.2% to 8%, effectively 
doubling its budget by 2010. 
However, the report also noted that the Department of Health began a programme in 
2010/11, of pay restraint, budget cuts and removal of various tiers of management, 
in order to deliver some of those cost savings. Spending was now set at 0.1% real 
increase per year until 2015/16, effectively an almost zero percent increase in the 
NHS annual budget for the next 5 years. 
There have been various estimates of the actual amount of increase needed by the 
NHS in order to meet the impact of various forces such as changes in the population 
or increasing medical technology. Such estimates can vary but Sir David Nicolson, 
Chief Executive of NHS England estimated [37] that continuing with the existing 
model of care, the NHS would have a shortfall of £20 billion by 2014 and an 
additional funding shortfall of £30 billion by 2020 (on top of the previous £20 billion 
shortfall). 
In their report “The NHS Productivity Challenge” [36], the King’s fund predicted that 
the NHS on its current trajectory, was heading rapidly towards a major crisis.  
 
2.2 Improving NHS productivity and efficiency 
The difficulties facing the NHS was more difficult that previously experienced, in part 
because of the unprecedented level of funding restraint, but this was also 
exacerbated by the major re-organisation occurring in the NHS at the same time. 
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Historically, trusts have attempted to meet budget shortfalls by reducing (often 
temporarily) the extent of their service provision, even though in the long term this 
may cause additional problems- for example, longer waiting list times by reducing 
the number of operations performed during periods of budget shortfall. However, 
with the current focus on delivering a high quality service, it is no longer deemed 
acceptable for trusts to do this.[36] 
The focus of the department of health, as well as many trusts, has been to utilise 
classic internal levers such as reducing the tariffs paid to hospitals, freezing pay 
increases, or placing a moratorium on new recruitment. However, with many of 
tactics already utilised, the NHS comes under increasing pressure to come up with 
innovative solutions for future productivity gains.   
The Health Select Committee in 2013 [38] identified that tariff savings – reducing 
payment-by-results prices to incentivise hospitals to cut costs, represented by far the 
largest factor in the efficiency savings – amounting to £2.4 billion per year.  
 
Figure 2 Health Select Committee planned savings: (Source – The King’s fund) 
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The tariff “efficiency factor” resulted in a real terms change in the tariff paid, despite 
the fact that the tariff received an annual inflation uplift. It has been estimated by the 
King’s fund [36], that this has resulted in real cuts in PbR prices of 6.3% between 
2010 and 2015. 
With the increasing pressure for providers to reduce costs, keeping costs contained 
is now essential for trusts to survive financially. The Institute of fiscal studies 
published a joint analysis in 2009 [39] which concluded that with no increases in 
funding, the NHS would be faced with an unprecedented need to close the financial 
gap through more efficient and effective use of its constrained budget. 
This was reconfirmed in the King’s fund’s 2010 analysis “Improving NHS 
Productivity: more with the same not more of the same”.[40] 
 
2.3 Issues with controlling the Tariff 
In order for trusts to control and reduce costs, it is implicit that such organisations 
must have a robust system of accounting in order to keep track of the costs and 
expenditures involved in activities related to the tariff. A better understanding of 
healthcare accounting is required to deliver cost saving within the NHS, however 
there are a number of limitations to conventional costing methodologies [41] 
The traditional method of unit cost analysis by the NHS has been utilising reference 
costs. Since 1988, the Department of Health has collected data on reference 
costs.[42] Reference costs have been submitted by individual trusts to the 
Department of Health, largely as a central means of calculating a national tariff for 
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medical conditions and procedures. Reference costs represented a ‘top-down’ 
approach to costing, where institutional costs are aggregated and analysed at the 
specialty or departmental level. Until recently, this has been the main tool for 
calculating costs in the NHS. However, to make the costing data more credible, the 
Department of Health (DH) has asked organisations to utilise Patient level 
Information and Costing System (PLICS). [43] 
Two new costing tools have been developed and are currently being implemented – 
Patient level Information and Costing Systems (PLICS) and Service line Reporting 
(SLR) [44]. Patient level costing systems have been introduced in the NHS since the 
mid-2000s. Patient level costing systems had their roots in the principle of Activity 
based costing (ABC), which developed in the United States in the 1970s and 80s, in 
the manufacturing industry. To date, not all trusts have computerised costing 
systems which allow them to track the individual costs incurred by each patient for 
each specific episode. Rather, most trusts collect aggregated information across 
different “service lines” or specialities.  It should be noted that Monitor, the sector 
regulator for health services in England, does not require full patient level costing 
such as PLICs, but rather Service Line reporting (SLR) which generates and output 
of profitability by each service line. SLR represents a more detailed analysis of 
financial data than the traditional top-down reporting. Service line reporting can be 
implemented without full patient level costing, at a potentially reduced cost, making it 
attractive to some trusts.[43] 
PLICs however, represents a method to calculate costs at the level of the patient 
episode, thereby allowing the linking of costs to clinical data, potentially making it 
more meaningful, as well as transparent. 
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It was estimated that by 2011, half of all NHS trusts had PLICS in the NHS [36]. A 
recent CIMA survey of trusts show that approximately 70% of NHS trusts have 
implemented PLICS and/or SLR [43], however the validity of its methodology has yet 
to be described in the medical or economic literature . 
 
2.4 Payment by Results 
The introduction of payment by results (PbR) in 2004/5 changed the fundamental 
nature of the provider-purchaser relationship in the NHS. With block contracts 
removed, trusts were now reimbursed for each individual patient treated, based on a 
set price per HRG code, which was reviewed on an annual basis and set, at least 
partially, on the basis of the reference costs reported.  
With this new system, it was important that the costing calculations of the trusts were 
increasingly robust, as ultimately, the tariff has to reflect the cost of the episode. As 
such, clinicians and managers need to understand how their clinical activity and work 
relate to the financial cost and outcomes.  
The introduction of PbR resulted in a drive to develop new tools to better link clinical 
activity with financial outcomes [45]. 
 
2.5 Top down and Bottom up costing 
In the top down costing model, costs are traditionally listed as direct costs, indirect 
costs or overhead costs. The top down model allocates overheads across different 
levels and departments, spreading the cost of such overheads. The danger of such a 
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model is that such overheads can represent unaccounted “black holes”, where 
unknown costs are aggregated and lost. In other cases, the overheads are regarded 
as fixed and therefore unalterable, simply because there is no transparency 
regarding them. 
Activity based Costing (ABC) represents an example of a bottom-up method of cost 
analysis. Under the ABC methodology, activities are identified and each activity has 
an assigned cost, dependant on the resources or services utilised by that activity. 
The main benefit of such a costing method is that it assigns indirect costs and /or 
overheads into direct costs, as compared to the top down method. 
With the ABC methodology, an organisation is better able to understand the different 
cost elements of its products and /or services. This would then allow the organisation 
to identify and/or eliminate activities which are unprofitable or ineffective, allowing for 
better productivity.   
A study in 2008 by Maiga and Jacobs [46] showed that ABC was significantly 
associated with improvements in quality, cost improvement and profitability. 
 
2.6 The use of ABC in hospitals in other countries 
It is perhaps unsurprising that the United States have a longer history of patient level 
costing, given their system of healthcare funding. The USA switched from a national 
social insurance programme (Medicare) to a DRG-based model for reimbursement in 
the 1980s. As such, the hospitals there, much like the UK hospitals after PbR was 
implemented, had strong incentives to account for and control their costs.  
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In Europe, countries such as Finland, Sweden, Germany and the Netherlands utilise 
a bottom-up costing methodology, while countries such as Austria, Estonia, France   
utilise a top-down methodology [47], while in Australia, Azoulay et al noted that a 
bottom up ABC method is used partially [48].  
 
2.7 Getting it Right First Time (GIRFT) 
In September 2012, Professor Tim Briggs and his team published the “Getting It 
Right First Time” report [35]. The report noted the increased financial pressures that 
were facing the NHS and also the increasing demand from patients requiring 
orthopaedic treatment. The report also highlighted the rising problem of litigation in 
the NHS. In particular, the report stated that 15% of all litigation claims reported were 
orthopaedic-related (having risen by over 60% in the last 3 years compared to 12% 
for overall medical litigation) and noted that the rising potential legal liabilities were 
unsustainable.  
A proposed network of hospitals and treatment centres, forming specialist 
orthopaedic units was recommended by the report. The cost of orthopaedic implants 
was also noted and it was suggested that by negotiating as a network, such costs 
could be reduced. 
The importance of improving orthopaedic theatre utilisation and efficiency was also 
highlighted in the report. This was seen as crucial to deliver the significant annual 
savings required by the NHS in light of the existing politico-economic climate. 
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Chapter 3 
The existing situation in 2012 
3.1 Payment-by-results and HRG Codes 
Payment-by-results, introduced in 2004 in England, dramatically changed the 
manner in which hospitals received their income. Patient events were now grouped 
together into events, termed a Healthcare Resource Group (HRG) consisting of 
events that consume a similar level of resource. A number of different surgical 
procedures, for example can be assigned to one HRG code.  
An example of the codes normally utilised for primary knee replacement are: 
Table 4: HRG Codes for TKR  
HRG HRG Label 
HB21A 
 
Major Knee Procedures for non Trauma 
Category 2 with Major CC* 
  HB21B 
 
Major Knee Procedures for non Trauma 
Category 2 with CC* 
  HB21C 
 
Major Knee Procedures for non Trauma 
Category 2 without CC* 
 
 *CC – Complications and Co-morbidities 
Such a HRG code would cover not just total knee replacements, but also for 
example, uni-condylar knee replacements and patella-femoral knee replacements. 
However, in order to get a HRG code for payment, 2 other codes need to be 
collected as well – the ICD-10 codes and the OPCS codes for the episode. 
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3.2  ICD-10 Codes 
The International Statistical Classification of Diseases and Related Health Problems 
version 10 is a compilation of medical codes for diseases, signs and symptoms, 
abnormal findings, complaints, social circumstances and causes of injury or disease. 
It was completed by the World Health Organisation in 1992 and consists of over 14 
400 different codes. This can be further expanded using sub-classifications. The 
ICD-10 does not classify procedures or interventions – this is the remit of the OPCS 
codes. 
3.3 OPCS codes 
The first classification of surgical procedures was produced in 1987 by the Office of 
Population Censuses and Surveys (OPCS). The current iteration being used within 
the NHS is version 4 (referred to as OPCS-4). OPCS-4 represents the procedural 
classification used by clinical coders in NHS hospitals to code operations, 
procedures and interventions performed on patients during their inpatient or day 
surgery stay. There are out-patient procedures coded by it as well. OPCS-4 remains 
an essential part of national databases such as Hospital Episode Statistics (HES) in 
England, but also in datasets in Wales and Scotland.  
OPCS-4 consists of a 4-character code similar to that found in ICD-10. Most 
orthopaedic procedures are coded with the first character ‘W’ representing bones 
and joints in the classification. 
An example of the OPCS codes relevant to knee replacement surgery would be can 
be found in the table below: 
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Table 5 OPCS Codes relevant to TKR  
 
Source: OPCS Procedures Relevant to the NJR [49] 
 
3.4 Calculation of the HRG Code 
ICD-10 codes, representing the co-morbidities, and OPCS codes, representing the 
procedure, are entered by the clinical coders in the hospital trusts to generate a HRG 
code for that admission episode. The computer programme then generates HRG 
code represents a national tariff, for which the NHS hospital and trust will be paid, for 
that patient episode. With advancing technology, the HRG code can also be 
generated using an App [50] by inputting the ICD-10 and OPCS-4 codes.  
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The tariffs are reviewed nationally and available for download from the Gov.uk 
website [51]. An example of the 2012/13 tariffs for primary knee replacement are: 
Table 6: HRG Tariff for TKR 
HRG HRG Label Tariff  
HB21A 
 
Major Knee Procedures for non-trauma 
Category 2 with Major CC* 
£7675 
  
 
HB21B 
 
Major Knee Procedures for non-trauma 
Category 2 with CC* 
£6377 
  
 
HB21C 
 
Major Knee Procedures for non-trauma 
Category 2 without CC* 
£5817 
 
 *CC – Complications and Co-morbidities 
Additional adjustments to the tariff are made utilising a market forces factor (MFF) 
multiplier, based on where the hospital or trust is located. This reflects the increased 
cost of providing services, in for example, Central London as compared to North 
Devon. The MFF multiplier for our institution (Imperial NHS Trust) was 1.2417 in 
2012/13. This may be modified further if the Best Practice Tariff (which is applicable 
to primary hip and knee replacements) applies. 
 
3.5 Information from Imperial Finance Department 
The Finance department at Imperial NHS Trust was approached in March 2012 in an 
attempt to obtain existing data regarding costs of total knee replacement done at 
Imperial NHS trust. At that time, the trust had not yet implemented PLICS, and the 
most up-to date data available was derived from a top-down approach. The following 
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data was provided by the Assistant Director of Finance at Imperial NHS Trust 
regarding the cost of knee replacements.  
Two sets of data were provided by the finance department. As can be seen from the 
first data set, total costs were distributed across the different service lines for the 3 
HRG codes relevant to total knee replacement. The method of data collection 
resulted in repeat entries in (for example, theatre minutes), representing costs from 
different theatre staff.  
Table 7: Top down breakdown of costs for HRG codes 
Cost Driver 
Total 
Cost 
HB21A 
Total 
Cost 
HB21B 
Total 
Cost 
HB21C 
Ward LOS 55,075 448,381 100,561 
T&O Prosthesis averaged total cost, 43,005 321,669 76,159 
LOS/attendances 26,475 320,435 56,254 
ward Other 26,314 219,123 37,750 
Consultant mins 22,702 132,739 26,534 
Theatre anaesthetic mins cx 20,759 114,369 24,147 
LOS 17,590 106,087 23,490 
Surgeon Theatre mins 16,786 90,939 18,628 
Therapy mins 12,398 58,081 14,259 
Theatre nursing mins CX 10,985 57,405 11,458 
Drug spend patient matched 8,571 54,522 9,790 
Theatre numbers 8,134 16,341 3,212 
Patient numbers 6,367 13,702 2,934 
Path request 4,846 13,493 2,223 
Blood 4,283 5,292 812 
Theatre mins CX 2,978 4,208 811 
Imaging requests 2,658 3,558 704 
ECG activity 971 3,392 244 
ECHO activity 896 2,258 118 
Theatre mins SPEC 110 608 209 5 
Theatre mins 480 283  
Total cost in £ 292,917 1,978,471 409,546 
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Subsequently, the finance department calculated the following data based on the 
total data above, divided by the total number of activities (i.e. cases) and allocated 
the cost for a single knee replacement as shown on the following table. 
 
Table 8: Cost of TKR according to top down method 
Cost Driver Cost 
per 
session 
Cost per 
patient 
Cost 
per 
bed-
day 
Costing 
Consultant 547 
  
274 
SPR 149 
  
75 
Anaesthetist 547 
  
274 
Theatre pay costs 886 
  
886 
knee replacement kits (J&J / Biomet) 
   
2400 
General theatre non-pay (i.e. dressings, 
sterilisation etc) 
 
1658 
 
1658 
Anaesthetic & recovery (i.e. airways, drugs 
etc) 
 
143 
 
143 
Inpatient ward - nursing pay & non-pay 
 
1724 244 1724 
Radiology 
 
120 
 
120 
Drugs 
 
36 
 
36 
Administration 
 
526 
 
526 
Pharmacy 
 
12 
 
12 
Pathology 
 
46 
 
46 
Therapies 
 
166 
 
166 
    
  
Contribution to Trust overheads 
   
8,339 
Estimated Trust overheads  
(conservatively estimated) 
   
1,000 
Total costs 
   
9,339 
Income – Tariff x Market Forces Factor 
(average of all 3 tariffs = £6623) x 1.24    £8212 
 
Net Loss    £1126 
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3.6 Significant financial loss 
As can be seen from the calculations provided from the finance department at 
Imperial, the trust was losing over £1100 for every knee replacement performed. The 
corporate overheads (£1000) estimated by the finance department were also noted 
to be on the conservative side, with any further increase making the loss even 
greater.  
According to the 10th Annual report of the National Joint Registry [52], Imperial NHS 
Trust performed 629 joint replacements in 2012. Assuming half of those are knee 
replacements, then the trust would have lost the significant sum £354 127 for the 
knee replacements which had been undertaken that year. 
Additional benchmarking data was provided by the finance department, comparing 
data obtained from other trusts regarding the cost of knee replacements there. 
Table 9: Benchmarking Data from finance department 
NHS TRUST 
 
Unit Cost 
 
CHELSEA AND WESTMINSTER HOSPITAL NHS 
FOUNDATION TRUST £10,603 
NORTH MIDDLESEX UNIVERSITY HOSPITAL NHS TRUST £9,345 
KINGS COLLEGE HOSPITAL NHS FOUNDATION TRUST £7,928 
PENNINE ACUTE HOSPITALS NHS TRUST £6,185 
PLYMOUTH HOSPITALS NHS TRUST £6,186 
ROYAL SURREY COUNTY HOSPITAL NHS FOUNDATION 
TRUST £6,109 
 
This data supported the view by the trust management that knee replacements were 
potentially a loss making procedure for the trust involved, especially in London. 
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3.7 Service Line Reporting 
Data from Service Line Reporting at Imperial was available from 2013. However, 
while more accurate, in theory, than the top-down data, there were still significant 
shortcomings in the data collected. Two examples of such service line data are 
provided in the Appendix.  
Example Patient A 
 
 
Example Patient B 
 
 
As can be seen from the breakdown, the estimated cost drivers still remain grossly 
inaccurate, with estimates such as consultant time spent daily estimated at 60 
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minutes per patient per day. Some patients did not have any physiotherapy cost 
allocated following the knee replacement.  
In both the examples in the appendix, total knee replacement was a loss making 
procedure for the trust, despite one of the patients staying only 3 days in hospital. 
 
3.8 Conclusion 
There was therefore a need to conduct research into obtaining a more accurate 
costing analysis for total knee replacements, to determine if the trust was indeed 
going over the tariff, and if savings could be made through analysis of the pathway 
for TKR. 
We therefore designed a study to provide an accurate costing analysis of the clinical 
pathway for total knee replacement (TKR) and determine where the major cost 
drivers lay.   
This would allow us to achieve the efficiency savings in line with the national 
productivity improvement programme. A recognised methodological costing 
approach could then be adopted in order to obtain more accurate estimates of 
treatment costs, as well as to inform future health economic evaluations, which in 
turn subsequently may guide national policy. 
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Chapter 42 
Activity Based Costing of Total Knee Replacements at a 
London Teaching Hospital 
4.1 Introduction 
The National Audit Office in the United Kingdom (UK) has recommended that 
efficiency savings of £20 billion must be achieved by the National Health Service 
(NHS) between 2011 and 2015 [53]. The challenge of achieving such savings in 21st 
century healthcare seems particularly demanding given the costs of caring for an 
ageing population and rising costs associated with the emergence of new medical 
technologies [4, 54]. This is especially true in orthopaedics, where there has been a 
consistent year-on-year increase in the number of hip and knee replacements [55] 
and the cost of primary hip and knee replacements, adjusted for inflation,  is 
estimated to have increased by 66% between 2000 and 2010 [56].  
 
4.2  Time-driven Activity based Costing 
Time-driven activity based costing (TDABC) was developed by Kaplan and Anderson 
at Harvard Business School [57]. It is a cost-calculation methodology that estimates 
                                                          
2 This chapter is based substantially or wholly on an article published in The Knee Journal: Time-
driven activity based costing of total knee replacement surgery at a London teaching hospital.  
Chen A1, Sabharwal S2, Akhtar K3, Makaram N4, Gupte CM . Knee. 2015 Jul 30. pii: S0968-
0160(15)00160-X. doi: 10.1016/j.knee.2015.07.006 
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the costs of activities based on the unit cost of supplying capacity and the time 
required to perform the service in question. Over the last 10 years, cost analysis 
research has evaluated newer technologies for TKR such as navigated knee 
arthroplasty [58], uni-condylar knee replacements [59], and more recently, custom 
made prostheses and instrumentation [60]. Such studies often use reference costs 
or top-down approaches to determine the cost of a TKR; however they lack the 
methodological rigor that micro-costing techniques such as TDABC offer. To date 
there is no published research that describes TDABC for knee arthroplasty in the 
UK.  
The primary objective of this study was to provide an accurate and clear costing 
analysis based on the TKR pathway. The secondary objective of this study is to 
determine what the major cost drivers are. 
 
4.3 Methods and Materials 
Twenty patients were prospectively observed through the in-patient TKR pathway 
(Figure 3) at a London teaching hospital. The orthopaedic department at this hospital 
performs approximately 250-300 total knee replacements a year. The inpatient 
pathway was selected as the focus of this study in order to allow comparison of 
actual cost of care with the HRG tariff for Total Knee Replacements (TKR). This tariff 
provides the hospital with remuneration for the inpatient stay only whilst outpatient 
visits attract a distinct and separate tariff [61] The inpatient pathway was mapped 
from the decision to admit the patient for a knee replacement to discharge of the 
patient from the ward. At each stage, all activities that related to the patient’s 
admission were recorded. 
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Figure 3: Summary of patient pathway for total knee replacement used to perform 
TDABC 
 
Detailed Process Maps of the pathways can be found in Appendix 2. These 
represent collaborative work with Chris Cheyne of Ernst and Young Management 
Consultants. Permission has been obtained for use in this thesis.  
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4.3.1 Personnel costing methodology 
At each stage in the patient pathway, personnel costs were calculated based on the 
time (minutes) spent performing activities related to the care of the patient. 
Whenever possible, this process was prospectively timed on the day. Where this 
was not possible, estimates of the timings were provided by interviewing the staff 
involved and obtaining consensus between the staff members regarding the amount 
of time required, in accordance with TDABC principles. The cost per minute of care 
for each member of staff was acquired from the hospital’s finance department and 
based on the NHS pay scale [62, 63].   
Annual personnel salary represented the average hospital spend for each type of 
staff member and included pension as well as national insurance contributions. 
Consultant cost per unit of time was based on an average of 430 sessions worked 
per year. Other staff costs per unit of time were based on an average of 42 weeks 
worked per year and the average time worked per week. Specialist registrars have a 
contribution of their salary provided by their training deanery and this was 
incorporated into their annual salary. Non-medical personnel annual salary included 
an average shift allowance increment. Salaries included the government mandated 
capital living allowance, London Weighting.  An example of cost per minute is 
demonstrated for operating theatre staff in Table 10.  
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Table 10: Theatre staff annual salaries and cost per unit of time  
 £ per annum Session
s per 
Year 
Sessions 
Per Week 
£ per 
session 
( 4 hours) 
£ per 
minute 
Orthopaedic Consultant  112,350 430 10 261.28 1.09 
Anaesthetist Consultant  112,350 430 10 261.28 1.09 
 £ per annum Weeks 
worked 
per year 
£ per week Hours 
worked per 
week 
£ per minute 
Specialist Registrar 53,495 ( after 
deanery 
reimbursement)  
42 1,273.69 48 0.44 
Scrub Nurse ( Band 6) 43,329 42 1,031.64 37.5 0.46 
Scrub Nurse 2 ( Band 5 ) 35,263 42 839.60 37.5 0.37 
Scrub Nurse 3 ( Band 5 ) 35,263 42 839.60 37.5 0.37 
Operating Department 
Practitioner ( Band 5) 
35,263 42 839.60 37.5 0.37 
Recovery Nurse (Band 
5) 
35,263 42 839.60 37.5 0.37 
Theatre Support Worker 
( Band 3) 
26,117 42 621.83 37.5 0.28 
Porter ( Band 2) 23,537 42 560.40 37.5 0.25 
 
 
4.3.2 Consumable costing methodology 
Medical consumables used at each stage in the patient pathway were cost at the 
discount price charged to our institution by the provider, as were the implant costs.   
The cost of the patient’s own medications was not included as it is the policy of our 
institution that patients are asked during pre-assessment to bring in their normal 
medication for use during the inpatient stay. Peri-operative antibiotic use and 
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analgesia was included and the hospital’s pharmacy purchase prices were used to 
cost these.  
1-in-4 patients required a blood transfusion and the cost of this is included in the 
breakdown. We did not differentiate between whether the anaesthetic or the surgery 
was performed by a consultant or a trainee under supervision. Such supervised 
training occurs regularly in the NHS and as such, the data should reflect this in order 
to obtain a more accurate costing model.  
 
4.3.3 Indirect costing methodology 
Departmental (ward-level) overheads that were not observable during the 
prospective evaluation of the patient journey through the total knee replacement 
journey, were acquired from the hospital estates department. This estimate was 
generated by dividing the annual spending on ward overheads by the number of 
bed-days per year allocated to the orthopaedic ward to provide a unit cost for a 
single patient bed-day in a year. Corporate overheads were estimated at 43.8%. This 
represents the proportion of the hospital’s expenditure on corporate spending. It 
includes building and content capital costs, non-clinical salaries, indemnity, operating 
theatre maintenance, expenditure on information technology, electricity, water as 
well as a large number of other services that are required to provide the 
infrastructure to operate a large healthcare institution. 
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4.4 Results 
4.4.1 Patient Demographics 
The mean age of the patients was 73.4 years (62-84, SD 6.29) and all patients were 
ASA grade 1 or 2. 14 patients were female, and 6 were male. 17 patients were ASA 
Grade 2 and 3 patients were ASA Grade 1. The mean BMI range was 30.4 (18.6-
39), 14 knees had a mean varus deformity of 5.32’ degrees (range 2.5-12.5) and 6 
knees had a mean valgus deformity of 10.83’ degrees (range 5-15). 12 patients 
underwent a cruciate retaining TKR and 8 had a posterior-stabilised procedure.  
 
4.4.2 Timings and Costings 
The timings and cost for personnel activities in the operative component of the TKR 
pathway are listed in Table 11. The total cost for this component of the TKR pathway 
in relation to staffing cost was £769.09. The total cost operating theatre consumables 
(including knee prosthesis) was £1862.32 with a breakdown listed in Table 12. The 
turn-around time for the pathway represents the time from the patient leaving the 
operating theatre to the next patient arriving into the anaesthetic room. The mean 
time for our study was 27.3 minutes (Range 11-45, SD 6.2). The cost of theatre staff 
during this turnaround time was estimated to be £176.70. 
 
Other components of the patient pathway included pre-assessment and joint school 
staffing costs which was estimated to be £153 based on staff time commitment and 
their cost per minute. The mean length of stay was 5.25 days (Range 4-7, SD 2.42). 
Post-operative care cost in relation to staff activities (doctors, nurses, 
physiotherapists and other allied healthcare professionals) was estimated to be 
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£601. In addition to daily staff activities, one of costs in in-patient care were 
estimated to be £209.41. These activities are summarised in Table 13. The 
orthopaedic ward overheads were estimated to be £58.84 per bed day. This estimate 
was generated from the finance department and it includes the cost of activities such 
laundry, cleaning and equipment maintenance.  
 
The total cost of direct patient care (personnel and consumables) in the TKR 
pathway as well as orthopaedic ward overheads was £3,994.35. Corporate 
overheads3 at 43.8% were valued at £1,651.47 and the total overall cost for inpatient 
care was estimated to be £5,421.95.  
 
 
 
 
 
 
 
 
                                                          
3 The figures for corporate and departmental overheads were provided by Chris Cheyne of Ernst and Young, 
based on figures provided by the finance department at Imperial NHS Trust.  
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Table 11: Timings and cost for personnel activities in the operative 
component of the TKR pathway 
Procedure Staff member Mean activity time ( minutes) Cost per minute (£) Total cost (£) 
Nursing admission Nurse (Band 5) 9 0.37 3.33 
Consent Anaesthetist 7.8 1.09 8.50 
Consent Surgeon 7 1.09 7.63 
Sending for patient Porter (Band 2) 6.3 0.25 1.58 
Portering time Porter (Band 2) 18 0.25 4.50 
Collection time ODP (Band 5) 3 0.37 1.11 
Anaesthetic preparation Anaesthetist 9 1.09 9.81 
 ODP (Band 5) 9 0.37 3.33 
Anaesthetic time Anaesthetist 22.1 1.09 24.10 
 ODP (Band 5) 22.1 0.37 8.178 
Scrub preparation time Scrub Nurse  
(Band 6) 
30.2 0.46 13.89 
 Circulator 1 (Band 5) 30.2 0.37 11.17 
Transition into theatre Anaesthetist 4.4 1.09 4.80 
 ODP (Band 5) 4.4 0.37 1.63 
Positioning time ( including 
catheter, planning and 
safety checklist) 
Surgeon 20.8 1.09 
22.67 
 SpR 20.8 0.44 9.15 
 Anaesthetist 20.8 1.09 22.67 
 ODP (Band 5) 20.8 0.37 7.70 
Surgical time Surgeon 98.4 1.09 107.26 
 SpR 98.4 0.44 43.30 
 Anaesthetist 98.4 1.09 107.26 
 ODP (Band 5) 98.4 0.37 36.41 
 Scrub Nurse (Band 6) 98.4 0.46 45.26 
 Circulator 1 (Band 5) 98.4 0.37 36.41 
 Circulator 2 (Band 5) 98.4 0.37 36.41 
Transition to recovery Anaesthetist 8.8 1.09 9.59 
 ODP (Band 5) 8.8 0.37 3.26 
Theatre clean up Scrub Nurse (Band 6) 12.6 0.46 5.80 
 Circulator 1 (Band 5) 12.6 0.37 4.66 
 Circulator 2 (Band 5) 12.6 0.37 4.66 
 TSW (Band 3) 12.6 0.28 3.53 
Recovery time Recovery nurse (Band 5) 132 0.37 48.84 
Total   1154.5  658.37 
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Table 12: Cost of theatre consumables 
Type of consumable Unit cost (£) Number used Total 
Cost(£) 
Combined spinal and epidural 
anaesthesia (Marcaine 0.5% 10ML) 
0.94 1 0.94 
Combined spinal and epidural 
anaesthesia ( Morphine 0.2mg) 
1 1 1 
Cefuroxime antibiotic (1.5g) 9.38 1 9.38 
Sterilised Tray 80 5 400 
Cement 50 2 100 
Cement mixer 45 1 45 
Standard knee procedure consumables 
(sutures ,swabs ,drapes , dressings) 
115 1 115 
Implant Cost 1191 1 1191 
Overall cost £1862.32 
 
 
 
 
 
 
 
 
 
 
 
Table 13: Ward Costs: 
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Expenditure Mean time taken 
(minutes) 
Staff involved Cost per minute (£) Total Cost (£) 
 
 
Patient Observations - 5.25 
days (60 mins per day) 
315 Band 4 0.33 104.48 
Consultant Ward rounds (10 
mins per day) 
53 Consultant 1.09 57.70 
SHO Ward Rounds (15 mins 
per day) 
79 SHO 0.51 40.48 
Update patient notes (SHO) 
53 SHO 0.51 27.15 
Preparation and 
administration of medication 
(35 mins per day) 
184 Band 5 0.37 68.66 
Cleaning of Wounds and 
Change of dressing 
40 Band 5 0.37 14.93 
First Mobilisation out of bed 
with physiotherapy (includes 
paperwork) 
45 Band 5 0.37 16.79 
Taking Bloods 
20 Band 2 0.25 4.98 
Updating patient notes 
(Nursing) 
158 Band 6 0.46 72.44 
Booking follow-up 
appointments 
10 Band 2 0.25 2.49 
Post-Operative X-rays 
15 Band 5 0.37 22.32 
Complete Electronic 
Discharge 
10 SHO 0.51 5.12 
Physiotherapy (first main 
session, teach exercises) 
45 Band 6 0.46 20.63 
Physiotherapy (subsequent 
sessions) 
158 Band 6 0.46 72.44 
OT Assessment 
30 Band 5 0.37 11.19 
PROMS data collection 
15 Band 6 0.46 6.88 
Ward Pharmacist (15 mins 
per day) 
79 Band 6 0.46 36.22 
Preparation of TTAs by 
Pharmacist 
30 Band 7 0.54 16.10 
TOTAL 
1339   £601 
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Table 14: Summary of total inpatient cost of TKR using ABC model 
TKR pathway component Total cost (£) % Of 
Total cost 
Pre-assessment/Joint School 163.18 3 
Admission and operating theatre staff 658.37 12.14 
Turn-around time 176.70 3.26 
Operating theatre consumables 1862.32 34.35 
Ward care (5.25 days) 601 11.09 
Orthopaedic ward overheads (5.25 days) 308.91 5.7 
Total (Direct and departmental overheads)  3,770.48 69.54 
Corporate Overheads at 43.8% 1,651.47 30.46 
Total Cost £5,421.95 100 
 
 
4.5 Comparison with Tariff paid 
The best practice tariff (paid for the inpatient pathway) for total knee replacement in 
a patient without co-morbidities in 2011/12 was £5224 (HB21C) and £5902 (HB21B) 
for patients with co-morbidities. The Market Forces Factor (MFF) for our institution, a 
central London hospital, was 1.2417, giving a total tariff of £6487 and £7929 
respectively. There is no direct correlation with ASA grade and the tariff; therefore 
the lower of the 2 tariffs (£6687) was adopted to compare institutional cost of 
treatment with the PbR reimbursement, as the majority of our patients were low 
anaesthetic risk with well controlled co-morbidities. Our institution makes an 
estimated profit of £1,065.05 per TKR based on the lowest tariff.  
The largest cost drivers in this activity based costing model were the operating 
theatre consumables and implant which represented 35.35% of the total cost. 
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Corporate overheads also represented a large proportion of overall cost at 30.46% of 
total cost. The costs of admission and operating theatre staff were 12.14% of the 
total cost of treatment. The combined ward cost (daily staffing activities, one off 
activates and ward-level overheads) was 16.79% of the total cost of treatment. 
 
4.6 Summary of costing results 
Using an activity based costing methodology; the total cost of a ‘non-complex’ TKR 
at our institution was estimated to be £5,421.95. When compared to the national best 
practice tariff, and with appropriate adjustment for market force factors, 
reimbursement was valued at £6,487. The institutional profit from treatment was 
estimated to be £1,065.05. The major cost drivers of treatment were determined to 
be cost of theatre consumables (including implant, which represented the greatest 
share of the cost), corporate overheads, overall ward cost and staffing costs for 
admission as well as the operating theatre. 
 
4.7 Comparison with other TKR Studies 
The first published costing study for TKR surgery was  performed over 30 years ago 
and estimated the total cost of inpatient treatment at £3868[64]. The authors of that 
study considered implant cost, other operating theatre consumables and the in-
patient bed cost per day. Cost per unit of time for all personnel involved in patient 
care and overheads were not incorporated into their costing methodology. While the 
estimated cost determined by their analysis may appear relatively low compared to 
our study’s findings, adjusting their estimate for inflation 30 years after they 
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published their research would yield a much higher cost which is likely be the result  
of their average inpatient stay. The mean duration of in-patient stay in the described 
study was 31 days. This seems quite radical when compared to current clinical 
practice that has demonstrated safe and efficient delivery of inpatient care can be 
accomplished with an inpatient stay of 3 to 4 days [65]. 
A more recent European multicentre study published in 2008 [66] estimated that the 
cost of primary knee arthroplasty in Austria amounted to £7366 in Germany to £6473 
and in Switzerland to £10,709. The authors of the study concluded that to lower 
costs further, implant and personnel expenses must be reduced as they were the 
major cost drivers.  The main limitation to this study was that their cost analysis 
methodology was not described in detail, and was only reported as data acquired 
from a survey of European Hospitals. A number of other published costing studies 
for TKR adopt costs or charges generated from hospital financial data, however the 
methods used to develop these costs are not described [67, 68]. An activity based 
costing model comparing custom made prosthesis and standard TKR in 2013 
estimated that the cost for in-patient treatment for standard instrumentation TKR was 
€5,546 however the methodology for generating estimates of time for activities was 
not described and indirect costs as well as overheads were not included in the 
overall estimate of cost [69]. 
Akhavan and Bozic [70] recently (2015) published a study on activity based costing 
in the United States for total hip and knee replacements. In that study, the overall 
cost4 of a knee replacement was estimated to be £9807. The top 3 cost drivers were 
implant costs - significantly higher than ours - at £3888, cost of stay in hospital 
£2245 and Operating Room (OR) costs at £1596. These costs were found to be 
                                                          
4 Converted at a rate of $1USD  to £0.67 GBP 
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significantly lower than costs estimated through traditional accounting (TA) (55% of 
costs from TA). 
 
4.8 Analysis of Cost Drivers 
Our study shows that the major cost drivers involved in TKR pathway are implant 
cost, operating theatre staff salaries, overall ward cost and corporate overheads. The 
cost of the inpatient stay was proportionally much smaller in our study compared to 
other cost analysis research, and this is likely to be related to the mean inpatient stay 
that we reported, which was approximately 5 days. This is almost a third the length 
of stay that was cited in a previous TKR cost analysis study that that identified length 
of stay as a major cost driver [71].  In light of the impact of length of stay on overall 
cost,  it is perhaps not surprising this subject has been a popular domain in knee 
arthroplasty research, with a number of studies  demonstrating how enhanced 
recovery protocols  reduce the length of stay without increasing readmission or 
complication rates [72-74]. Similarly, implant cost which is another major cost driver 
for TKR has also been the focus of research and discussion within the orthopaedic 
community [75, 76]. It has been suggested that analysis of data from national joint 
registries has the potential to identify less costly implants with comparable clinical 
and functional outcomes and this will allow health services to achieve cost savings 
and maintain an expected standard of clinical care [76].  
Corporate overheads, calculated to be 43.8% of total direct patient cost and 
departmental overheads, is a substantial proportion of the total cost of the 
procedure. This expenditure probably relates to the structure of our institution which 
consists of three hospitals at different sites. The services these hospitals provide 
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include Level I trauma care and tertiary subspecialty treatment for cardiology, 
oncology and paediatrics. The corporate overheads for healthcare institutions such 
as ours are likely to be very high and a more cost efficient service may be achievable 
with independent orthopaedic treatment centres. These hospitals may provide lower 
corporate overheads, however their inability to provide acute medical and critical 
care services that are on par with those of larger healthcare institutions is probably 
their biggest drawback.  
Another cost driver that we evaluated was the operating theatre turnaround time. 
Although it forms a small part of the overall cost (3%), the fact that TKR is such a 
commonly performed procedure with 90,000 a year performed in the UK  [55],  
means that such inefficient practices are likely to result in a sizeable waste in 
expenditure by the health service as a whole 
 
4.9 Conclusion 
Our research has demonstrated an activity based costing methodology that 
incorporates a detailed account for cost per unit of time of hospital personnel and a 
breakdown of individual consumables used in the patient pathway. Such micro-
costing is considered the most robust approach in estimates of healthcare treatment 
cost [77]. Furthermore we have also incorporated indirect costs and corporate 
overheads into our methodology. Other studies in this field have adopted top-down 
estimates of cost which are easier to acquire however are often viewed as less 
accurate estimates[78]. The benefits of more accurate costing approaches for TKR 
extend beyond healthcare accountancy and cost analysis research. Cost of 
treatment is used to generate health economic evaluations which in turn guide 
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healthcare policy at a national level. Health economic evaluations in knee 
arthroplasty often adopt national reimbursement tariffs for the cost of treatment[79] 
or costing data that fails to detail cost per unit of time in relation to medical personnel 
or consumables other than the knee prosthesis [80]. Appropriate costing 
methodology is an important component of health economic evaluation quality [81] 
and deriving cost data from an activity based costing approach should add value to 
future cost minimisation, cost effectiveness  and cost utility research in knee 
arthroplasty. 
This is the first study to apply TDABC to estimate the cost of TKR in the United 
Kingdom. The success of applying these methods to a small cohort of TKR patients 
underlines the potential for larger studies with more heterogeneous patient groups to 
better inform policy makers attempting to benchmark treatment costs more 
accurately. Based on our findings, the institutional cost of a ‘noncomplex’ TKR in 
patients without substantial medical co-morbidities was £5,421.95, representing a 
profit of £1,065.05 based on a best practice tariff of £6,487. Larger studies which 
include more heterogeneous patient groups have the potential to better inform policy 
makers how to benchmark treatment costs more accurately    The major cost drivers 
of treatment were determined to be cost of theatre consumable (including implant), 
corporate overheads, overall ward cost and staffing costs for admission as well as 
the operating theatre. Appropriate discounting of implant costs, reduction in length of 
stay by adopting an enhanced recovery program and control of corporate overheads 
through the use of elective orthopaedic treatment centres are proposed approaches 
for reducing the overall cost of treatment. 
 
72 
 
4.10 Study Limitations  
There are 3 main limitations to this study. Firstly, corporate overhead costing was not 
derived from micro-costing methodology and was estimated to be a fixed value of 
43.8% of direct treatment and ward-level overhead costs. This estimate was 
acquired from SLR data provided by the trust finance department. This was 
performed because direct costing of these overheads is not practical and there is a 
paucity of economic evidence or consensus on appropriate methodology to 
determine these costs[82]. The value we used in our cost calculation represented the 
proportion of annual institutional expenditure that was attributed to corporate 
overhead costs. Secondly, the estimate of cost of a TKR generated from our 
research is unlikely to be applicable as a secondary data source for economic 
research. Corporate overheads estimates are specific to our institution and therefore 
the overall cost of treatment cannot be transferable to other healthcare institutions or 
services. Despite this, our study demonstrates a thorough micro-costing 
methodology that future costing studies may adopt as a template. Thirdly, the patient 
cohort selected from this study represented a small ‘noncomplex’ sample based on 
surgical and medical factors. Our cost estimate is therefore not representative of 
treatment costs for technically more challenging TKRs or for medically frail patients.   
As such, generalising the profitability of this procedure based on our study findings 
would not be appropriate for policy makers. However, future research that adopts 
these methods in larger and more heterogeneous patient populations would be 
important in benchmarking more accurate tariffs that accommodate patient and 
surgical factors which may influence overall cost.  
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Chapter 5 
Pathway Analysis and potential savings 
5.1 Introduction 
Primary total knee replacement is a routine, elective surgical procedure to replace 
the weight-bearing surfaces of the knee joint. There is good evidence that primary 
total knee replacement is an effective and cost-effective procedure to relieve pain 
and improve mobility [79, 83] 
As shown in Chapter 2, hospital reforms in the UK have led to an increased reliance 
on accounting practices, in order to deliver the efficiency improvements necessary in 
the current politico-economic climate.  
The demand for knee replacement surgery has continued to increase [56] placing 
the spotlight on the ability of hospitals to accurately allocate departmental costs 
directly to patients.  
Bottom-up costing has been shown to be more accurate in a hospital setting [84] 
[85]. Another, more recent, study in 2014 comparing 2130 procedures utilising a 
bottom-up activity based costing method versus a top-down method of cost 
calculation found that bottom-up method was more sensitive to at the patient level, 
supporting the previous research. [86].   
Akhavan and Bozic [70] evaluated TDABC costing versus Traditional accounting for 
arthroplasty surgery (total hip and total knee replacements). They found that TDABC 
calculations were significantly less than those derived from traditional accounting. 
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The cost of a total knee replacement using TDABC were 55% of those derived using 
traditional accounting. Differences were noted in every cost category, from implant 
costs, room and board, operating room services as well as drug and service costs. 
 
5.2 TDABC at Imperial and Implant costs 
Our study, described in Chapter 4, has shown that the cost of a primary TKR is 
covered by the tariff, and that total knee replacements can indeed be a profitable 
endeavour for the hospital. Furthermore, further collaborative work with Ernst and 
Young5 at our institution have also shown that the cost of both first and follow-up 
outpatient attendances are also covered by the tariff. The TDABC cost estimates for 
new patients is £127 and for follow-ups is £45. Process maps for the inpatient and 
outpatient pathway have been included in the Appendix 2.  
Our study has shown that theatre consumables – predominantly the implant costs is 
the main cost driver for total knee replacement at our institution. Within our 
institution, at the time of the study, there were 3 different knee replacements being 
utilised. The 3 knee replacements were the PFC Sigma knee replacement by Depuy, 
the Genesis 2 knee replacement by Smith and Nephew, and the Biomet AGC knee 
replacement. The first 2 implants were the most widely used, with approximately 
60% of surgeons utilising the Depuy PFC knee replacement. The Biomet AGC was 
only used by one surgeon at the trust, with the remaining utilising the Smith and 
Nephew Genesis 2 implant. 
                                                          
5 Collaborative work; permission given to be included in thesis by Chris Cheyne of Ernst and Young and Anne 
Hall, Senior Surgical Manager at Imperial NHS Trust. 
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There was significant variability in the cost of these knee replacements, with the 
lowest price implant being the Smith and Nephew Genesis 2.  
Table 15: Comparative cost of Knee replacement implants 
Type of Knee Replacement Base Cost Additional Cost 
compared to lowest price 
implant 
Smith and Nephew Genesis 2 £1191 N/A 
Biomet AGC £1233 +£42 
Depuy PFC Sigma £1812 +£621 
 
It should be noted that the Smith and Nephew Genesis 2 does have 1 additional 
base cost, not shared by the other implants. The pins used as part of the knee 
replacement surgery (which are included in the other implants) are costed 
separately, and an additional £50 needs to be factored in when using this implant. 
This makes it slightly more expensive than the AGC by £8, but still cheaper than the 
PFC by £571. 
It should be noted that the revision rates of the Genesis 2 and PFC knee 
replacements at 10 years from the 12th Annual NJR report are comparable – 2.67% 
(2.4-2.97 95% CI) for the Genesis 2 and 2.66% for the PFC (2.55-2.77 95% CI). The 
AGC has a slightly higher revision rate of 3.55% (3.29-3.82 95% CI).  
The AGC knee replacement is no longer being used at Imperial NHS Trust, following 
presentation of the collaborative work on TDABC of primary knee replacements. 
Given the similar revision rates of the Genesis 2 and PFC knee replacements, a 
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strong argument can be made for moving from the current dual provider system, to a 
single provider system (using the Genesis 2). Such a move would also increase the 
volume based discount for that knee replacement without any change in capacity.  
Our costing study showed that each additional day in hospital costs £249.23 
(including corporate overheads), and this represents only a 4.6 % increase in the 
overall cost of treatment. An Enhanced Recovery Programme (ERP) had not been 
implemented at our institution at the time of the study, however even if the length of 
stay had been brought down from an average of 5.25 to 3 days using an ERP this 
would result in savings of £560.77, which represents less cost efficiency when 
compared to using the cheaper implant. It is also unlikely that significant further 
gains can be made in this area. Therefore, from our cost estimates, it appears that 
not only is implant cost one of the strongest cost drivers within the TKR pathway, but 
it is likely to be the one that is most easily controlled.  
 
5.3 National Variability in implant costs 
Professor Timothy Briggs has highlighted the variability of implant costs nationally. In 
a letter as President of the British Orthopaedic Association in June 2015 [87], he 
noted that based on NJR data from 2013, implant prices across England for 
cemented total knee replacements had a variation of £943 to £1164 (excluding VAT). 
As VAT (at 20%) was chargeable, the more expensive the implant, the greater the 
overall cost because of VAT.  
This variability is supported by further financial information obtained from the Elective 
Orthopaedic Centre. The Elective Orthopaedic Centre is an NHS treatment centre 
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providing elective only orthopaedic surgery. It was established by four South West 
London acute trusts to deliver high quality orthopaedic treatment. According to the 
12th NJR report, the EOC performed 3093 joint replacements in 2014. By contrast, 
our institution (Imperial NHS Trust) performed 629 joint replacements in 2014. 
 
5.4 EOC financial data 
Financial data was provided by Steve Thomas, managing director of the EOC in 
2013 for comparison with the data obtained from our costing study. The data from 
the EOC, was similar to the data obtained from the Finance department at Imperial 
NHS Trust. It represented a top-down costing analysis of the cost of a total knee 
replacement at the EOC. 
While not directly comparable, it does provide some insight into the efficiency of one 
of the largest specialised Orthopaedic units in the country. 
The cost of a knee replacement at the EOC was estimated to be £6485. Implant 
costs were noted to be £1067, and theatre staff costs for the case were noted to be 
£795. The average length of stay was 4 days, at a daily estimated bed-rate of £186 
per day. While the overall cost of a knee replacement done at the EOC is higher than 
in our TDABC study, it should be noted that this represents a top-down calculation of 
costs there. Both our study and that of Bozic [70]has shown that such calculations 
tend to over-estimate costs, and it is likely that that an ABC analysis of the costs at 
the EOC would be lower than the figures above. 
A personal communication from the managers at the EOC has confirmed that the 
implant costs stated above refers to the cost of the PFC Sigma implant. At Imperial, 
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the cost of this implant would be £1812, representing an additional premium of £745.  
However, as implant discounts are related to volume, it should be noted that the 
EOC performs almost 5 times the number of joint replacements than our institution.  
 
 
5.5 EOC Surgical Timing data 
Data was also provided by the EOC for comparison of theatre efficiency. The data 
provided represented the information collected by the theatre management database 
of 200 patients operated on by 2 consultants at the EOC in 2011/12. This data is 
retrospective and relies on accurate data input by the theatre nursing staff, who are 
required to do this in addition to their other duties in theatre, at the EOC, but 
nevertheless allows some comparison of the overall efficiency of the theatre set-up 
as compared to our unit. The data collection software at the EOC does not, for 
example individually record the sending, portering or collection times and so the data 
from our study was combined for comparison. Further demographic details such as 
age, BMI, extent of deformity (varus/valgus) were not available. 
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Table 16: EOC Timing Data 
 EOC Mean Imperial Mean 
ASA Grade 1.96 1.85 
Sending/Portering / 
Collection time 
5.15 mins 27.3 mins 
Anaesthetic Preparation 
time 
2.35 mins 9 mins 
Anaesthetic time 11.79 mins 
 
22.1 mins 
Transition into Theatre 
time 
11.15 mins 4.4 mins 
Surgical positioning and 
scrubbing time  
8.63 mins 
 
20.8 mins 
Surgical Time 64.83 mins 98.4 mins 
Transition to Recovery 
time 
8.24 mins 8.8 mins 
 
Total Surgical Time  per 
TKR 
 
112.49 mins 
 
190.8 mins 
 
5.6 Analysis of EOC data 
The implant costs at the EOC are significantly lower than that paid for the same 
implant at our institution - almost half the cost (£1067 compared to £1812). This is 
largely due to the discount the EOC gets for its high purchase volume.  
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In addition, while the surgical data available from the EOC is not as robust as the 
data from our TDABC study, comparison between the two shows that the mean time 
for a knee replacement at the EOC is significantly less that that at Imperial. 
While the data shows differences in anaesthetic times and surgical times between 
the two institutions (favouring the EOC), it may be difficult to replicate such 
differences for a number of reasons. Surgical timings can be surgeon-dependent, 
and there is no information regarding whether the procedures were performed by 
consultants or trainees under supervision. Furthermore anaesthetic timings have a 
similar dependence on the anaesthetist in question, and while the patients are ASA 
grade 1 or 2, this system of anaesthetic grading remains a crude measure of the 
ease (and hence speed) of the anaesthetic procedure.  
However, it should be noted that the theatre scrub team at the EOC specialise only 
in elective orthopaedics, whereas the nursing staff at our institution are orthopaedic 
trained, but also have to be trained to cover other general theatres. As such, it may 
be that the greater specialisation of theatre staff plays a part in the improvement of 
the anaesthetic and /or surgical timings. 
A more feasible area for efficiency improvement would be to reduce the turn-around 
times. As noted from the data, the sending/portering/collection times are 
considerably longer in our institution (an average difference of 22 minutes) between 
the patient being sent for, and arriving in the anaesthetic room. This is likely to be 
due to the set-up of the EOC, where patients are kept in a waiting area directly 
adjacent to the operating theatres, whereas at Imperial, the inpatients are kept on 
the ward on the 7th floor, with the operating theatres being on the 13th floor. In 
addition, the EOC employs an additional Band 3 member of staff for every 3 theatres 
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to assist in the clean-up and re-stocking of supplies, freeing up the theatre scrub 
staff to prepare for the next case, allowing for swifter turn-around. It is felt that the 
expense of the additional member of staff is outweighed by the gain in turn-around 
time and general theatre efficiency. 
A more detailed study, however, would be required for accurate comparison between 
our two institutions.  
 
5.7 GIRFT National Review of adult elective orthopaedic services 
in England  
In March 2015, Professor Tim Briggs and the British Orthopaedic Association (BOA) 
published the pilot review of the GIRFT programme [88] . Following visiting 205 
hospitals by the GIRFT team, the report noted that significant numbers of surgeons 
performing primary and revision hip and knee replacements had low minimum 
activity volumes, despite evidence that higher volume activity leads to better 
outcomes.  
The report noted evidence of a huge, inexplicable variation in choice and cost of 
implants, the negative impact of the loss of ring-fenced orthopaedic beds and the 
loss of experienced dedicated orthopaedic theatre teams. 
The recommendation of the report was for surgeons to be more aware of the impact 
of implant choice on cost. The report also recommended the creation of elective 
orthopaedic centres such as the EOC or the RNOH at Stanmore, in order to bring 
together surgeons undertaking significant volumes of both routine and complex 
cases. 
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In addition to these recommendations, the report also notes the dramatic increase in 
healthcare litigation and the urgent need to address the huge potential liabilities. 
According to NHSLA data, orthopaedic litigation in 2012/13 had the second highest 
expenditure, after obstetrics [89]. The report confirms that the GIFRT team and the 
Royal National Orthopaedic Hospital (RNOH) at Stanmore, would be reviewing both 
NHSLA data as well as cases that leading clinical negligence law firms have entered 
into their databases, with regard to hip and knee claims in trauma and orthopaedics. 
5.8 Further recommendations for improving the overall TKR 
pathway. 
As part of the collaborative work with E &Y, we determined that the conversion rate 
for new patients to surgery was only 24% in the consultant-led outpatient clinic. A 
possible recommendation for improving the pathway would be the establishment of 
an extended-scope practitioner clinic, for both new patients and surgical follow-ups. 
The cost of an ESP being less than a consultant, this would free-up more consultant 
time for in further clinics or theatre.  
Reducing cancellations would be another recommendation of the work. Between 
July 2012 and February 2013, the cancellation rate on the day of surgery was 
10.3%. While some cancellations may be outside of the department’s control, with 
this level of cancellations, further research into the cause of these cancellations and 
methods of mitigation is indicated. It is estimated that a cancellation on the day of 
surgery for a total knee replacement costs the trust £2011, as seen in the breakdown 
below.   
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Table 17: Cancellation costs 
Financial Impact of cancellation of TKR 
on the day of surgery 
 Cost 
Cost of unproductive theatre time for one 
TKR case  (with overheads) 
£ 658 x 1.438  £946 
Loss of potential profit from case  £1,065 
Total loss to trust  £2011 
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Chapter 66 
Litigation costs in Knee Surgery – a review of the 
NHSLA database 
6.1 Introduction 
The National Health Service litigation authority (NHSLA) was established in 1995 to 
indemnify as well as manage both clinical and non-clinical claims against the 
National Health Service (NHS). 
Clinical claims arising out of incidents occurring after 1 April 1995 are handled under 
the “Clinical Negligence Scheme for Trusts” (CNST), a voluntary risk-pooling scheme 
for NHS trusts, Foundation trusts and PCTs. Claims relating to incidents from before 
April 1995 are handled under the “Existing Liabilities Scheme” (ELS), now funded 
centrally by the Department of Health. 
The NHSLA database contains information on all claims (including potential claims 
or “incidents” where a formal letter of claim has not been received but a patient has 
indicated their intention to pursue a claim) notified to the NHSLA by member NHS 
bodies, whether open or closed. 
                                                          
6 This chapter is based substantially or wholly on an article published  in The Knee Journal: The cost 
of adverse events from knee surgery in the United Kingdom: an in-depth review of the National 
Health Service Litigation Authority database. Chen A1, Patel NK2, Khan Y, Cobb JP, Gupte CM. 
Knee. 2015 Sep;22(4):286-91. doi: 10.1016/j.knee.2015.04.011. Epub 2015 May 23. 
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In 2011/12, the NHSLA received 9,143 claims (including potential claims) under its 
clinical negligence schemes and 4,618 claims (including potential claims) in respect 
of its non-clinical schemes. The figures for 2010/11 were 8,655 and 4,346 
respectively. The NHSLA had 22,512 “live” claims as at 31 March 2012, and clinical 
claims are now settled in an average of 1.3 years from the date of notification to the 
NHSLA to the date when compensation is agreed or the claimant discontinues their 
claim.  [90] 
In 2011/12, the NHSLA made payments totalling £1,330 million in respect of all of its 
schemes. It should be noted that these figure relates only to expenditures incurred 
by the NHSLA itself. Surgery, obstetrics / gynaecology and medicine respectively, 
represent the highest numbers of claims against the NHS. As at 31 March 2012, the 
NHSLA estimates that it has potential liabilities of £18.9 billion, of which £18.6 billion 
relate to clinical negligence claims. [89]  
In 2012/13, the NHSLA made payments totalling £1,309 million in respect of all of its 
schemes. This trend for payments totalling over a billion pounds annually has 
continued, with payments across all schemes totalling £1, 244 million in 2013/14 and 
£1,223 million in 2014/15. The NHSLA notes that approximately 35% of cases were 
dropped by claimants and 47% settled out of court. Only just over 2% involved 
courtroom litigation, with 15% remain outstanding [90]. 
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Figure 4 – The total value of pay outs from all litigation cases against the NHS 
(Source: NHSLA) 
 
 
 
 
 
 
 
Litigation continues to be a major issue in healthcare worldwide. The number and 
value of claims against the National Health Service (NHS) have been significantly 
increasing over the last 30 years (NHSLA). 
 
6.2 Studies on Orthopaedic Litigation 
There are only a limited number of published studies on litigation in orthopaedic 
surgery. Both Khan et al [91] and Atrey et al [92] gave a general overview of 
orthopaedic costs. Khan et al reviewed 2117 cases arising between 1995 and 2001. 
They concluded that the commonest causes of claims were post-operative 
complications, wrongful diagnosis, inadequate consent and incorrect-site surgery. 
Atrey et al examined 2312 cases arising between 2000 and 2006 and suggested that 
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many of the successful claims had a preventable cause. Other studies include Raine 
et al [93], who reviewed 195 cases involving children finding that delayed diagnosis 
of severe sepsis was the commonest cause of successful litigation, often leading to 
death and considerable cost to the NHS. Quraishi et al [94] reviewed data on spinal 
litigation finding that it continues to be a significant cost to the NHS, partly because 
of the massive legal fees required to resolve these complex cases. Finally, Khan and 
Giddins [95] analysed claims involving hand and wrist surgery and found the majority 
of claims were for routine carpal tunnel and wrist fracture surgery, with none for 
complex cases.  
When considering hip and knee surgery, there are only two previous studies in the 
literature. Bhutta et al [96] reviewed hip and knee arthroplasty litigation over a 5 year 
period. They found that successful claims results from inadequate consent and 
deviation from policies or routine practice, which should be addressed while 
maintaining high technical expertise. More recently, McWilliams et al [9] reviewed 
litigation after hip and knee arthroplasty in the NHS and found that the commonest 
reasons for litigation were neurological deficit and infection respectively. Albeit with 
increasing operation numbers, the number of claims has not increased. Rather than 
all knee surgery, they only examined knee arthroplasty, for which claims for infection 
have decreased but those for technical errors and dissatisfaction were found to be 
increasing. To our knowledge, there are no studies examining litigation for all knee 
surgery (elective and trauma) cases. 
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6.3 Aims of the Study 
The aim of this study was determine causes and costs of litigation related to 
orthopaedic surgery of the knee spanning an incident period from 1996-2009. We 
also sought to determine the likelihood of successful litigation for any particular event 
and predict future costs from open cases.  
 
6.4 Methods and Materials: 
Data was requested from the NHSLA under the Freedom of Information Act (2000). 
A database of all orthopaedic surgery claims in England and Wales reported to the 
NHSLA between 1st April 2005 and 31st March 2010, with incidents ranging from 
1996 to 2009, was obtained. The database included both closed (settled and/ or 
completed) and open (outstanding) claims up to 31st December 2010. For each 
claim, there were details of the incident and notification dates, a brief description of 
the incident, cause, injury, specialty and location of the incident. The total amount 
paid out, including separate figures for damages and claimant and defence costs, 
was also provided for each closed claim. Exclusion criteria included all cases 
unrelated to knee surgery and lack of detail on the type of surgery and/ or the nature 
of the incident.  
 
6.5 Analysis 
The database was searched for all cases involving surgery to the knee. The cases 
were then collated and initially categorised based on whether it was elective knee or 
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trauma surgery, then subsequently the type of surgery undertaken. Within each 
surgical category, the cases were further divided into groups based on the nature of 
the claim or the incident, as provided by the brief description.  The number of 
successful closed cases in each category was used to calculate the total cost of that 
type of incident.  
The litigation success rate was calculated based on the number of closed cases 
where damages were paid out divided by the total number of closed cases. The 
potential future cost for that type of incident was calculated as the litigation success 
rate multiplied by the number of open cases for that incident. Further analysis was 
based on the type of surgery undertaken and the nature of the claim or incident 
(according to the description).  
In order to provide a context for the chances of successful litigation, odds ratios were 
calculated based on the litigation success rate of the event against the litigation 
success rate for infection (as a denominator base). This is because infection remains 
one of the most significant adverse events that can occur in TKRs and other 
orthopaedic operations, and for primary TKR has been quoted at 0.86% [97].   
 
6.6 Statistical analysis 
Statistical analysis was performed using SPSS 20.0 (SPSS Inc., Chicago, Illinois, 
USA) for Windows. Unless otherwise stated, categorical variables are expressed as 
frequency (percent), and continuous variables are expressed as median (range). All 
costs are in Great British Pounds (GBP, £). 
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6.7 Results: 
We identified 515 cases involving knee surgery; out of a total of 4609 cases.52 
cases were excluded as they were too vague or non-specific with regards to the 
incident or the type of surgery to the knee.  
 
Figure 5: No of claims by year of incident for knee surgery 
 
The table represents the number of knee claims reported to the NHSLA. It should be 
noted that there is a 3 year window (from the time the claimant knows or ought to 
have known that he has cause for a claim) for him/her to file a claim. As such the 
smaller number claims from 2007-2010 may represent claims that have not yet been 
filed. The small number of claims prior to 2002 may represent the fact that litigation 
claims were handled ‘in-house’ until 2002/2003, and data from those claims are not 
fully available to the NHSLA. 
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6.7.1 Knee Replacements 
A total of 298 cases (58% of all included knee cases) related to knee replacements 
were recorded in the database, with 90 cases remaining open. The total pay-out so 
far of £10.45 million for 208 closed cases. Future pay-out for arthroplasty was 
estimated at £3.382 million. 
Figure 6: The total pay-out for TKR claims according the type of incident  
 
 
 
 
 
 
 
 
Nerve damage 
20 cases were noted, with 12 involving foot drop. The remaining 8 cases had 
unspecified ‘nerve damage or pain from nerve damage’ as the cause for litigation. 15 
cases had been closed, with a total pay-out of £694,744 (Median £69,272, range 
£974- £216,466). Of the fifteen cases, 9 paid out, suggesting a successful litigation 
rate of 60%. Future liability of the open cases was therefore estimated at £138,948, 
based on the median pay-out. 
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Wrong Prosthesis used or Equipment 
42 cases were listed with 31 cases closed. 19 cases involved an oversized 
component (predominantly femoral) and 2 cases involved a right sided femoral 
prosthesis being inserted into a left knee. Of those 2 cases, one was noticed intra-
operatively and revised on-table, albeit with a fracture caused as a result of the 
revision.  2 cases were based on the wrong implant was ordered but not noticed until 
intra-operatively. Over half these cases - 26 cases (63%) - were added to the 
NHSLA database after 2007. The total pay-out for all 41 cases was £ 1 443 534 
(median £61,066) with a litigation success rate of 77%. Future Litigation costs 
estimated at £470, 212. 
 
Misalignment of Components 
9 cases went to litigation, with 7 closed so far. A total of £637, 504 (Median £84, 131, 
range £19355-£391, 567). The most expensive pay-out accounted for over half the 
total costs paid – in that case, £391, 567 was paid out for misalignment secondary to 
an incorrect tibial slope cut, necessitating revision surgery. Litigation success rate 
was 71% with future damages estimated at £130,102. 
 
Infection 
Infection (not resulting in amputation) accounted for 37 cases, with 29 cases closed. 
The total pay-out was £1,352,620, median £33,222, range £1916-£399,260).  Nine 
cases were noted as the claimant having contracted a Methicillin Resistant 
Staphylococcal Aureus (MRSA) infection, the others cases did not specify the 
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organism.  The success rate of litigation was 42%. Future damages estimated at 
£111, 626. 
 
Drain left in Knee 
3 cases were found of a drain left in the knee. All 3 cases underwent further surgery 
to remove the drain. Total pay-out was £48,462 (Median £8295, range £5255 - 
£34914). Litigation success rate was 100%. 
 
Foreign Body (Cement) 
There were 4 cases of residual cement left in the knee following replacement. 1 case 
remained open. Of the 3 closed cases, there was only one pay-out - £8250. Future 
damages are estimated at £2750 (litigation success rate 33%). 
 
Amputation 
There were 20 cases of amputation following TKR (13 cases closed). The largest 
total pay-out was for amputation - £2 132,097 (median £190,795, range £414-
£447,713). 20 cases were found. Infection was cited as the cause for the amputation 
in 17 cases. There was one case which noted popliteal artery transection as the 
cause of the amputation. Of all incidents following TKR, amputation resulted in the 
largest individual pay out of £447,413 for MRSA infection and the largest total pay-
out of £2.13million. There were 11 pay outs and the median was £190,795. 
 Litigation success rate was noted at 62% and future costs estimated at £841,249. 
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Physiotherapy-related 
There was only one case (closed) of a knee dislocating allegedly because of the 
physiotherapist on the first post-operative day. There was no pay-out. 
 
DVT/PE 
A total of 12 cases involved deep venous thrombosis (DVT) and/or pulmonary 
embolism (PE). 4 cases remained open. Of the 8 closed cases, a total of £217,667 
was paid out in 3 cases (Median £72,121, range £12,500-£133,057). The majority 
were DVT (9 cases), with 5 PEs and insufficient information in 3 cases. In the 3 
cases that paid compensation, one alleged the DVT was caused by poor mobility, 
one case blamed failure to provide post-operative anti-coagulation and the last case 
blamed a failure to provide thrombo-elastic (TED) stockings as the cause for the 
event. 
 
Anaesthetic Issues 
There were 3 cases (all closed) relating to anaesthetic complications. A total of 
£342,044 was paid out (Median £171,022, range £100,209-£241,835). Two cases 
involved complications from spinal or combined spinal/epidural anaesthesia and one 
case from a pneumonia following a chest infection from a general anaesthetic. 
 
 
95 
 
Renal Failure 
There were 5 cases of renal failure (1 open), paying out a total of £76, 150 (Median 
£27,628, range £18,522-£30,000). Litigation success rate was 75%. Future 
payments are estimated at £19, 037. 
 
Intra-operative Ligament or Tendon damage 
There were 6 cases (3 open). Only one pay-out was made for complete laceration of 
the patella tendon (£151,359). Litigation success rate was 33% and future pay-outs 
estimated at £151,359. 
 
Intra-operative Fracture 
There were 3 cases (all closed) of fracture. Total pay-out was £70,531 (Median 
£30,840, range £4853-£34,838). One case involved excessive femoral notching, the 
second case involved a fracture of the patella. The final case did not specify the 
fracture site. 
 
Post Operative Fracture 
 
There were 5 cases in the database of fractures following TKR. Only 2 pay-outs 
were made totalling £23,264 (Median £11,632). Litigation success rate was 40%. 
Both successful cases involved a failure to diagnose the fracture. 
 
 
96 
 
Poor outcome / Alleged negligence  
 
A large number of cases (114 or 38% of all TKR cases) fell into the poor outcome or 
alleged negligence category. Both categories were collated, as by definition, in order 
for a claim to be successful, negligence or a sub-standard level of care had to be 
proven. A total of 77 cases (23 open) were found where no further details beyond 
alleged poor outcome or negligent surgery of the knee replacement. In those cases, 
a total of £884,896 was paid out in 42 cases (Median £36,871). The litigation 
success rate was 45%.   
 
A further 40 cases were noted to have poor outcome or alleged negligent surgery 
and went onto have further surgery. These 20 cases paid out a total of £1,453,880 
(Median £72,694). The litigation success rate here is 74%.  
 
Future Costs were estimated at £132,734 and £591,729 respectively. 
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Table 18 – Summary of median pay outs, litigation success rates and odd 
ratios of TKR events. 
 
The total costs stated in the above table (and also subsequent tables in this chapter) 
represent the total sum paid out, including the damages, defence costs and claimant 
costs. 
 
6.7.2 Projected future pay outs 
Future pay out for TKR was estimated to be £2.71 million based on those cases that 
were not yet closed. The 3 highest future costs arose from amputation, poor 
outcome/ alleged negligence with further surgery and incorrect prosthesis (Figure 4).  
TKR Event 
 
 
Closed (n) Litigation 
Success rate 
 
Odds 
Ratio  
 
Total pay 
out 
£ 
Median 
(Range) 
£ 
Drain left in knee 3 100% 2.38 48,462 8,295 
(29,657)  
Incorrect prosthesis 31 77% 1.83 1,465,595 61,066 
(317,954) 
Renal failure 4 75% 1.79 76,150 27,628 
(11,478) 
Poor outcome – surgery 20 74% 1.76 618,525 72,694 
(3077-
192,501) 
Malalignment 7 71% 1.69 637,504 
 
84,131 
(375,110) 
Anaesthetic issues 3 67% 1.60 342,044 171,022 
(141,626) 
Intra-operative fracture 3 67% 1.60 47,044 30,840 
(29,984) 
Amputation 13 62% 1.48 2,132,096 190,795 
(447,299 
Nerve damage 15 60% 1.42 694,774 69,272 
(215,492) 
Poor outcome - no surgery 54 45% 1.07 1,720,250 36,871 
(252,546) 
Infection  29 42% - 1,352,620 
 
33,222 
(397,344) 
Post operative Fracture 5 40% 0.95 23,264 11,632 
(9778) 
DVT/ PE 8 38% 0.90 217,677 72,121 
(120,557) 
Ligament/ tendon damage 3 33% 0.79 151,369 - 
Foreign body (Cement) 3 33% 0.79 8250 - 
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Figure 7 – Projected future estimated pay outs for TKR 
 
 
 
 
Table 1 showing litigation success rates of TKR adverse events 
 
 
 
6.7.3 Partial Knee Replacements 
Only 11 claims specifically noted that the case involved uni-condylar knee 
replacements (UKRs). No events were found for patella-femoral replacements. 
There was one case of nerve damage following UKR resulting in a pay-out of      
£27, 195. One claim involved a dislocated spacer which did not result in a pay-out.  
There were 3 closed cases which involved the patient having had a uni-condylar 
replacement when a total knee replacement was indicated, with two of the three 
cases subsequently having their UKR revised to a total knee replacement. Only one 
case of these 3 cases paid out, although the amount -£660,738- was considerable.  
There was one claim where a patient had a total knee replacement instead of the 
UKR as originally scheduled for (total pay-out £104,888), although it was also 
alleged in this case that the TKR was negligently performed. 
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6.7.4 Arthroscopy 
There were 63 (12%) cases related to knee arthroscopy identified from the database. 
Serious incidents such as amputation, incorrect site surgery and burns resulted in 
100% successful litigation rates. The single highest pay-out was for an above knee 
amputation following popliteal artery transection which occurred during knee 
arthroscopy and synovectomy. The total pay-out was £1,448,186. 
11 cases were found of post-operative infection (3 open) paid out a total of £306,019 
(Median £63,329, range £3926-£155, 967). The cases involved either delay in the 
diagnosis of the infection or a failure to warn of potentially increased risk of infection 
in that patient. The litigation success rate was 63% and future pay-outs are 
estimated at £119,692. 
4 cases were found of foreign bodies left within the knee (2 pieces of arthroscopic 
instruments and 1 scalpel, 1 not specified). Total pay-out was £81,989 (median 
£40,959, range £7000-£74,919, litigation success rate 67%). 
There were 3 claims for lack of consent (1 open) which resulted in a single payment 
of £950 for allegedly failing to consent for a lateral release. 
There were 5 cases of arthroscopy being performed on the wrong knee. 1 case 
remained open, but all the 4 closed cases paid out a total of £92,770 (median 
£22,684, range £9770-£37632). 
There were 4 claims where further surgery was required to correct problems from the 
original arthroscopy. No further details were available as to the 
problems/complications. 2 of these claims were successful and paid out a total of 
£51,862 (median £25,931, range £20,188-£31,674). 
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One claim for failing to remove a medial plica was successful (pay-out £12,228). 
Other claims include poor outcome and knee pain following arthroscopy (9 cases), 
diathermy burns (3 cases) and deep venous thrombosis (2 cases). 
Table 19 - Summary of median pay outs, litigation success rates and odd 
ratios of arthroscopy events  
Arthroscopy 
 
Closed 
(n) 
Litigation success rate  
 
Odds 
Ratio 
Total pay 
out 
£ 
Median 
(Range) 
£ 
Amputation 1 100% 1.58 1,448,148 - 
Incorrect knee  4 100% 1.58 92,770 22,683 
(24,175) 
Burns  1 100% 1.58 6800 - 
Foreign body 
left in knee 
4 67% 1.06 81,919 40,959 
(67,919) 
Infection 8 63% - 306,019 63,329 
(152,041) 
Consent 2 50% 0.79 950 - 
Further surgery 4 50% 0.79 51,862 25,931 
(11,486) 
Poor outcome/ 
pain 
6 33% 0.52 49,931 24,965 
(47,927) 
DVT/ PE 2 0% 0.00 - - 
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6.7.5 ACL Reconstruction 
A total of 24 cases were found in the database, with 15 cases closed. Total pay-out 
was £873,936. There was one case of foot drop (total pay-out £218,019), 
representing the single highest pay-out. 5 cases of infection following surgery were 
found (2 open) with only one pay-out (£85,338), which relates to a failure to 
prescribe antibiotics. 4 cases (1 open) of a retained foreign body; a single pay-out of 
£17,994 was made for a retained wire. The other 2 cases involved small pieces of 
plastic and were unsuccessful.  
Regarding technical issues in ACL surgery, there were 3 cases involving incorrect 
screw placements cost £151,867 (Median 75,993, range £47,170-£104,697, litigation 
success rate 67%) and 3 claims for poor tunnel placement which paid a total of 
£138,867 (median £69,433, range £43,334-£95,533, litigation success rate 67%).  
There were 6 cases of poor outcome/alleged negligence with no further information – 
only one case has been closed (total pay-out £243,119). There remains one case, 
still open, with consent as the main focus of the litigation, discussed below.  
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Table 20 - Summary of median pay outs, litigation success rates and odd 
ratios of ACL reconstruction events  
 
ACL 
 
 
 
Closed 
(n) 
Litigation 
success 
rate 
 
Odds Ratio 
 
Total pay 
out 
£ 
Median 
(Range) 
£ 
Alleged negligence- 
failed surgery 
1 100% 
 
3.03 243,119 - 
Nerve damage 
 
1 100% 
 
3.03 218,019 - 
Failure to diagnose 
ACL rupture on 
arthroscopy 
1 100% 
 
3.03 18,728 - 
Screw Position 
 
3 67% 
 
2.03 151,867 75,993 
(57,526) 
Tunnel position 
 
3 67% 
 
2.03 138,867 69433 
(52,199) 
Foreign body left in 
knee 
3 33% 1.00 17,944 - 
Infection 
 
3 33% 
 
- 85,338 - 
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6.7.6 Trauma to the Knee 
There were 62 cases related to knee trauma. The majority of claims (41 cases) 
involved delayed or misdiagnosis. Only 5 cases of alleged negligent surgery (3 
closed) following fracture fixation and 2 of mismanagement of fractures were found 
in the database.  
There were 11 cases (1 open) of missed ligament or meniscal damage paying out a 
total of £301,790 (median £25,251, range £315-£104, 626, litigation success rate 
70%). 19 cases (4 open) of missed fractures of the knee joint paid out a total of 
£307,321 (median £23, 766, range £1890-£131,240, litigation success rate 67%). 
Other cases included 2 missed tendon ruptures - £151,237 (median £75,618, range 
£65,773-£85,464),  
A patient with hip arthritis and subsequently had an unnecessary knee arthroscopy 
cost £34, 571 and a surgeon who failed to diagnose an ACL rupture on arthroscopy 
cost £18,728.  
The highest single pay-out was for delayed diagnosis of popliteal artery transection 
and compartment syndrome following dislocation of the knee (£520, 136).  
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Table 21 - Summary of median pay outs and litigation success rates of knee 
trauma events 
Trauma 
 
Closed 
(n) 
Litigation success rate 
 
Total 
Pay out 
£ 
Median, 
(Range) 
£ 
Arterial damage & 
compartment syndrome 
1 100% 
 
520,136 - 
Ruptured tendon 2 100% 
 
151,237 75,618 
(19,691) 
Unnecessary operation 1 100% 34,571 - 
Missed ligament or 
meniscal 
Pathology 
10 70% 
 
301, 
790 
25,251 
(104,311) 
Missed fracture 
 
15 67% 
 
307,321 23,766, 
(129,350) 
Negligent surgery 
 
3 67% 
 
133,815 66, 907 
(93,662) 
Mismanagement 1 0% 0 - 
 
6.7.7 Miscellaneous 
Consent 
12 claims (3 open) were found involving issues of consent following knee surgery. 5 
cases involved total knee replacements, 1 case involved a uni-condylar knee 
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replacement, 4 cases involved arthroscopies and 1 case involved ACL 
reconstruction, with the final case involving non-specified surgery to the knee.  
Of the TKR cases, 2 of them involved lack of consent for spinal anaesthetic 
complications. Only 2 claims (failure to warn of risk of foot drop following TKR and 
failure to warn of increased risk of infection in a diabetic) had consent as the main 
reason for the claim; the remaining cases also cited other elements such as 
negligence or substandard performance of the actual surgery.    
One case, which still remains open, involved lack of consent for a Bone-Tendon-
Bone (BTB) harvest from the patient’s other leg, following damage to the original 
BTB graft in an ACL reconstruction. 
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Table 22 - Summary of median pay outs and litigation success rates of 
miscellaneous events (excluding consent) 
Miscellaneous 
 
Closed 
(n) 
Litigation 
Success 
rate 
 
Total 
Pay out 
£ 
Median 
(Range) 
£ 
Incorrect site  2 100% 
 
6,700 3350 
(4300) 
Delayed diagnosis (infection) 
 
2 100% 
 
409,957 204,978 
(233,644) 
Lost microbiological samples 
 
2 100% 
 
129,014 64,507 
(23,126) 
Fall from table 1 100% 8,600 - 
Bone tumours 
 
6 75% 
 
338,985 
 
22,359 
(356,324) 
 
 
Wrong Site 
There were 2 cases of the wrong knee being operated on, with no further information 
on the type of surgery. Both cases have been closed. In both cases, the correct knee 
was also operated on during the same procedure. Total pay-out was £6700, 
averaging £3350 per case. 
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Bone Tumours 
6 cases were found of delayed diagnosis of primary bone tumours, with 2 cases 
remaining open. The total pay-out was £388,985 (median 22,359, range £5151-
£361,475) in 3 of the 4 closed cases.  (75% litigation success rate) 
 
Delayed diagnosis (non-trauma) 
 
2 claims for missed deep infections paid out a total of £409, 957 (median £204, 978, 
range £88,156-£321, 800) and 2 lost microbiology samples which delayed the 
diagnosis of infection paid out a total of £129,014 (median £64,507, range £52,944-
£76,070). 
 
Other claims 
 
There was one claim (still open) which related to chondrocyte implantation in the 
knee. The allegation here relates to lack of information regarding weight-bearing 
following the procedure. Finally, there was one successful case of a patient falling off 
the table following administration of anaesthetic, injuring his arm and shoulder. The 
cost to the NHS was £8600. 
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6.8 Discussion 
Our analysis of the NHSLA database has demonstrated that litigation success rates 
are highest for technical errors such as incorrect prosthesis size, malalignment and 
retained drains than those involving known risks or factors not entirely in the 
surgeon’s control, such as infection and venous thromboembolism. This supports the 
findings by McWilliams et al [9] that litigation due to technical errors is increasing and 
that due to infection is decreasing. 
Khan and Giddins [95] also noted that the number of claims in hand and wrist 
surgery has been increasing. Our study shows that, for knee surgery, this does not 
appear to be the case. The number of claims until 2002 was also partly limited by the 
fact that NHS trusts dealt with smaller claims internally until then. There is a lag time 
between the incident occurring and the claim being registered with the NHSLA 
database. This is usually between 2-3 years, but in some cases is considerably 
longer, likely accounting for the cases whose incidents are in the 1990s. This lag 
time likely accounts for the tailing down of claims from 2008-2010.   
Infection was used as the denominator base for the Odds Ratios as infection 
remains one of the most significant adverse events that can occur in both knee 
replacements and other orthopaedic surgery. The incidence of deep infection 
following a primary TKR is 0.86%[97].   
Analysis of the litigation success rates and odds ratios suggest that technical errors - 
such as wrong prosthesis size, misalignment and drains being left in the knee have a 
much higher rate of claimants being successful than allegations which known risks or 
factors not entirely in the surgeon’s control, such as infection or DVT/PE. The high 
rate of renal failure pay-outs may be skewed as the number of cases was relatively 
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small (5 claims) compared wrong prosthesis (41 claims) or poor outcome resulting in 
surgery (40 claims).  
With regard to the poor outcome category, those resulting in further surgery have a 
much higher litigation success rate (74% compared with 45%), possibly because 
having further surgery suggests there exists a technical problem that can be fixed. 
These findings are in keeping with what one would intuitively feel represents a fair 
outcome for clinical negligence.  
Scott et al [98] commented that up to 20% of total knee replacement patients are not 
satisfied with their outcome. Our data suggests that this figure may be higher - the 
number of claims from the database with poor outcome who do not go on to have 
further surgery represents nearly 26% of the claims for knee arthroplasty.   
 
6.9 Issues with Consent 
Both Atrey [92] and Khan [91] noted that failure to obtain adequate informed consent 
was a significant problem in the management of orthopaedic patients. Atrey found 78 
cases where the main reason for litigation was a poor consent process. Compared 
with the 2312 cases he reviews, this represented 0.03% of the successful litigation. 
In our study, there were 2 cases of TKR where consent was cited as the main 
reason for litigation, against 131 successfully knee replacement claims, represents 
0.015% of cases.  There were 10 other cases where the consent process was noted 
to be involved in the claim. This represents 0.02% of the knee cases we analysed. It 
is interesting that all the cases involved elective knee surgery. It may be that patient 
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expectation plays a significant contributory role in this, although this is purely 
speculative.  
Incorrect prosthesis was a common source of litigation in TKR, predominantly 
oversizing of the femoral component. Bhutta et al [96] briefly mention wrong sizing of 
knee prostheses as an adverse event in their arthroplasty study but it was grouped 
with other events such as wrong site surgery and poor technique requiring revision 
into a single “operator error” factor. This may, in part, account for the lower litigation 
success rate of this factor (34%) in Bhutta’s analysis. Furthermore, Bhutta’s study 
reviewed claims from 2002-2007 and a significant number of these claims (63%) 
occurred after 2007. This may also contribute to the difference in our litigation 
success rates. It also suggests that such claims may be on the rise. 
 
 
6.10 Never Events and Wrong Site Surgery 
 “Never events” are defined as ‘serious, largely preventable patient safety incidents 
that should not occur if the available preventative measures have been implemented 
by healthcare providers’[99]. “Never events” have been defined, and in use, by the 
NHS since 2009, and initially, with regard to surgery, there were only 2 – wrong site 
surgery and retained foreign objects post operation. In March 2011, the list for “never 
events” was expanded to 25, and a third category was added to surgery – that of 
wrong implant or prosthesis. 
There were 7 claims for wrong site surgery, of which 5 were in arthroscopic surgery. 
There were no claims for wrong site surgery in TKR. One explanation for this could 
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be that arthroscopy is a short duration, high turnover procedure where there is a 
higher frequency of changeovers of patients and therefore a greater risk of error.   It 
would be of value to identify the key parts of the arthroscopy patient pathway where 
potential human errors are more likely to be made, with a view to providing additional 
safeguards to prevent these. One such safeguard that has been instituted since 
2008 is the World Health Organisation Surgical Safety checklist.   
With relation to retained foreign objects, 3 drains and 4 pieces of loose cement were 
retained following knee replacement surgery, while 4 foreign objects were found after 
arthroscopic surgery. The success rate of litigation in these cases was generally high 
– 100% for the drains and 67% for the arthroscopic cases. Loose cement cases 
were less successful, with only 33% of claims succeeding. 
 
 
6.11 Prosthesis Size and Side 
We identified 41 cases in the new category – wrong implant or prosthesis.    The 
Department of Health defines this category as the “Surgical placement of the wrong 
implant or prosthesis where the implant/prosthesis placed in the patient is other than 
that specified in the operating plan either prior to or during the procedure. The 
incident is detected at any time after the implant/prosthesis is placed in the patient 
and the patient requires further surgery to replace the incorrect implant/prosthesis 
and/or suffers complications as a result of the surgery. ” The only 2 exclusions are 
where the surgeons intentionally deviates from the operating plan and places a 
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different implant for clinical reasons, or where the implant is placed as intended but 
only later discovered to be suboptimal. 
The significance of this category of adverse event has not previously been 
highlighted by the previous studies in the literature. They represent almost 14% of 
the claims involving knee replacements and with £1.45 million paid out, the third 
highest pay-out from knee replacements. Of equal concern is that the litigation 
success rate for this category is high (77%), representing the second most 
successful area of claims after retained drains for knee replacements.  
The results show that there were 2 incidents where the wrong sided implant was 
placed in the knee and 2 cases where a failure of inspection of the equipment prior 
to surgery resulted in the claim. These would fit with the principle of the “never 
event”. The majority of cases, however, involved the wrong sized component being 
used. Yet a strict reading of the criteria would suggest that such cases would be 
classified as “never events”. The exclusion where the implant is place as intended 
would seem not to apply, as it would be expected that the non-negligent surgeon 
would have the clinical judgement to ensure the implant was of the correct size, and 
hence it cannot be argued that the implant was only discovered to be sub-optimally 
sized later on. This is supported by the high litigation success rate. 
Further clarification by the Department of Health would be helpful in this regard, as 
our findings could represent a serious potential safety issue if defined as it is. 
Related to this, our study demonstrates that litigation is more likely for an oversized 
prosthesis than for fracture following notching of the femur. As stated above, the 
litigation success rate for these incorrect implant or prosthesis cases is high (77%), 
second only to retained drains in TKRs.  
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6.12 Conclusion 
To our knowledge, there are no studies highlighting this adverse event in the 
literature. Possible solutions to this may include pre-operative templating on all 
patients which may reduce incorrect sizing and facilitate equipment ordering. In 
addition, employing a separate written surgical check list (like the WHO Surgical 
Safety checklist [100] for surgeon and nurse, which involves a check of equipment 
and implant type/ size pre- and intra-operatively.  
Our study highlights the substantial cost of missed or delayed diagnosis of knee 
pathology to the NHS, with 60 cases and a total cost of £2.90 million. This is 
surprising given the increased availability and capability of imaging modalities. With 
increasing numbers of patients with knee pathology and procedures, this area of 
litigation could continue to increase. There is an argument for early imaging in 
patients, which although has been shown to be cost and clinically effective [101], 
may also reduce litigation rates. With increasing numbers of patients with knee 
pathology and procedures, this area of litigation could increase without vigilance. 
 
 
6.13 Limitations of the study: 
The NHSLA highlighted when providing the database that it was designed primarily 
as a claims management tool rather than for risk management purposes or clinical 
research. As such the details provided in the description was often limited or 
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incomplete. The data was completely anonymised, leaving no way to follow-up that 
particular claim. Information on the hospital, region, the grade of surgeon involved 
and other clinical information was not available. Furthermore, where more than one 
allegation was present e.g. lack of consent and substandard surgery, it was not 
possible to determine the contributory amount of each separate allegation.   
The claims listed are specific to the NHS and the legal system in England. As such 
extrapolation of the analysis to other health and legal systems may not be viable. 
It should be also be noted that until 2002, lower value clinical negligence claims were 
handled in-house by trusts and the NHSLA may not therefore have complete data 
with relation to those claims.  
The number of certain cases was relatively small, which may skew results and make 
them less generalizable. For example, there was a higher success rate from renal 
failure (5 cases) compared to malalignment (9) or poor outcome resulting in surgery 
(40).  
Finally, claims may be started, abandoned or settled irrespective of the validity of the 
clinical incident and as such, caution should be exercised in drawing direct clinical 
conclusions from a medico-legal database. 
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Chapter 77 
The cost of repeating x-rays  
7.1 Introduction: 
Osteoarthritis represents a complex musculoskeletal disorder with multiple genetic, 
constitutional and biomechanical risk factors. It represents the most common form of 
joint disease in the elderly and ranks amongst the top 5 causes of disability [2]. The 
prevalence of knee osteoarthritis in patients aged over 45 in the general practice 
setting has been estimated by Bedson et al in 2005 at 12.5% [102] 
The diagnosis of knee osteoarthritis is based on clinical history and examination, 
followed by radiographic examination of the knee [103]. These radiographs can be 
taken with the patient supine or standing. The Kellgren-Lawrence Grading Scale is 
one objective measure that can be used to assess knee osteoarthritis severity on 
plain radiograph [104] Studies have shown that standing/weight-bearing (WB) views 
of the knee improve the detection of joint space narrowing more reliably than supine 
views [104]. This is probably because WB places compressive stresses on the knee 
joint that help accentuate any loss of articular cartilage causing joint space 
narrowing. However, it is not known whether knee radiographs requested by the 
general practitioner are routinely performed WB or non-WB in UK hospitals. 
                                                          
7 This chapter is based substantially or wholly on an article published in Springer Plus: Should all 
elective knee radiographs requested by general practitioners be performed weight-bearing? 
Chen A1, Balogun-Lynch J2, Aggarwal K3, Dick E4, Gupte CM5. Springerplus. 2014 Dec 2;3:707. 
doi: 10.1186/2193-1801-3-707. eCollection 2014. 
 
116 
 
Professor Briggs highlighted in his report ‘Getting it right first time’, that GPs routinely 
had a workload where 15%-30% of the consultations will be of a musculoskeletal 
nature [35]. With regard to requesting musculoskeletal investigations, in a survey of 
GPs in 2003 by Bedson et al [105], 50% of GPs were confident of diagnosing 
osteoarthritis on the basis of the plain radiograph. Furthermore, 80% of GPs were 
likely to request a radiograph if considering referral to an orthopaedic surgeon. The 
radiological report of the GP-requested knee radiograph is therefore pivotal in 
determining whether onward specialist referral is undertaken. The radiology report is 
however, influenced by whether WB or non-WB views are taken [104]. 
The Royal College of Radiologists have published guidelines on the indications for 
various imaging investigations, including those of plain radiography of the knee. In 
an audit of 1153 knee radiographs requested by GPs, only 50% of those radiographs 
fell within the RCR guidelines [106]. Morgan et al noted [106] that in 87% of cases, 
there was no change in management, apart from continuation of symptomatic 
treatment. GPs in Morgan’s study reported medico legal reasons as a significant 
factor in unnecessary radiograph requests. One further reason that management 
may not have changed in the case of knee radiographs, could be that non-WB views 
were taken, which did not fully the reveal joint space loss from degenerative change 
that WB views would have revealed. 
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7.2 Aims: 
The aims of this study were to: 
1. Quantify the number of and cost of repeating radiographs for the diagnosis of 
osteoarthritis of the knee at our institution, a major London teaching hospital. 
2. To confirm whether WB and/or skyline views significantly change the formal 
report by a radiologist regarding the presence of osteoarthritis, given the 
reliance of GPs on such reports to make the diagnosis of osteoarthritis. 
3. To determine how many radiology departments in London have implemented 
policies on routinely performing WB views on knee radiograph requests 
suspecting osteoarthritis.  
 
7.3 Materials and Methods: 
7.3.1 Aim 1: 
All patients over the age of 40, undergoing radiographic imaging at our institution of 
the knee were included in this retrospective cohort study. All traumatic cases were 
excluded, as were patients with any previous fixation or arthroplasty involving the 
knee. Knee radiographs taken between 1st January 2011 and 31st December 2011 
were included in the study.   It was not the policy of the radiology department at our 
institution, at the time of the study, to routinely perform WB or skyline views of the 
knee unless specifically requested to do so by the clinician. 
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Radiographs were examined to identify if they were WB or non-WB. All patients who 
then had subsequent WB knee radiographs after an orthopaedic consultation in the 
following 12 months were identified.  
The cost of these repeat procedures was calculated based on financial information 
provided by the radiology department. The radiation dose was calculated utilizing a 
sample of patients to find the average radiation dose in millisieverts (mSv) patients’ 
received whilst having a knee radiograph. 
7.3.2 Aim 2:  
All patients who initially had non-WB radiographs of the knee, then subsequently had 
repeat radiographs with WB and/or skyline views, were noted. The radiographs of 
these patients were then reported by a consultant radiologist at our institution. The 
consultant radiologist was asked to grade the severity of each radiographic feature 
between 1 (least severe) and 5 (most severe). A pro-forma containing a list of the 
commonly reported information in radiology reports of the knee from Bedson et al 
[107] was used by the consultant as a template for the reporting (see Appendix 3). 
This also included criteria from the Kellgren-Lawrence Grading Scale for knee 
osteoarthritis [104]. Results of non-WB vs WB radiographs of the knee were 
analysed.  
Statistics were by SPSS (version 20).  As the data was discrete and non-parametric 
a chi-squared test for trend was employed to analyse for significance with a p<0.05. 
7.3.3 Aim 3:  
A telephone survey of 35 acute NHS hospitals in the London region was conducted 
during a two-week period. The list of these trust was obtained from the NHS choices 
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website [108]. The superintendent radiographer of each hospital was asked if their 
department had a protocol for routinely performing WB anterior-posterior (AP), and 
lateral radiographs of the knee suspecting osteoarthritis. Details of the protocols for 
each department contacted were recorded. 
 
7.4 Results: 
7.4.1 Aim 1: Radiographs performed for GPs & repeats 
Of the initial 2,086 patients who had knee radiographs requested their GP, 118 were 
excluded, leaving 1,968 included in the analysis. The mean age of the patients was 
61.7 years (SD 12.5). 
Of the 1968 patients, 2.3% (n=45) of patients had their initial radiograph specifically 
requested by their GP to be performed as a WB radiograph. 
56 patients had an initial GP requested non-WB radiograph, and subsequently had 
repeat WB radiographs performed at the request of the orthopaedic surgeon.  
 
7.4.2 Aim 2: Radiologist reporting  
Joint space narrowing was reported as more severe on the WB radiographs when 
compared to the non-WB radiographs, and this difference reached statistical 
significance (p=0.035). All the other characteristic features seen on knee radiographs 
suggesting osteoarthritis showed a trend to be more severe on the WB views (except 
loose bodies), but these did not reach significance (p>0.05). 
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Figure 8: Graph to show the comparison between WB and Non-WB radiographs on 
formal reporting.  
*represents p<0.05. 
 
7.4.3 Aim 3: Telephone Survey results 
Of the 35 radiology departments included in the survey, 19 (54%) had a protocol in 
place for routinely performing WB AP radiographs on patients. Within this group, 2 
departments (6%) would only perform WB AP views if the request form indicated 
suspected osteoarthritis. One department had an age dependent policy, whereby 
only patients over 30 would have WB AP views performed routinely. Departments 
with no protocol in place would only perform WB AP radiographs on patients if a WB 
view had been specifically requested by the GP. None of the departments performed 
skyline views routinely.  
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7.4.4 Cost calculations 
The cost of repeating a second radiograph (AP and Lateral view only) was calculated 
at £22. As 56 repeat radiographs were performed during Jan 2011-December 2011, 
this equates to an extra £1232 added cost to the department. The time cost to the 
radiographer over this period was calculated to be 9 hours 20 minutes (based a 
mean of 10 minutes for each extra set of radiographs). 
The quoted radiation dose for a standard chest radiograph is 0.02 mSv [109]. The 
average extra radiation dose received by a patient having an AP/Lateral film was 
calculated to be 0.0107 mSv, approximately half that of a standard chest radiograph. 
Applied across all London hospitals the added cost of repeat radiographs in the 16 
London hospitals without WB protocols would be £19,712. Extrapolating this to 46% 
of the 168 NHS trusts in the UK, this would equate to an extra unnecessary direct 
cost to the NHS of £95,208 per annum. Extrapolating this to include the 353 NHS 
hospitals in England, this cost would be £200,052. In the current politico-economic 
climate, this saving, while modest at an individual hospital level, still represents a 
significant and unnecessary cost to the NHS, which can be readily and easily 
addressed by a local change in policy. 
 
7.5 Discussion: 
This study shows that, in the absence of a departmental policy for routinely 
performing WB knee radiographs, the vast majority of non-traumatic knee 
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radiographs requested by GPs in patients over the age of 40 are performed non-WB 
(98%).  
Our department sees approximately 1000 new knee patients annually. Of these 
patients, approximately 300 patients in (in 2012) would fit our inclusion criteria (age 
over 40, no previous arthroplasty or fixation, no trauma). Therefore, as a 
representation of patients seen by our department for suspected knee osteoarthritis, 
19% (56 out of 300) require an unnecessary repeat of the knee imaging at the time 
of their outpatient visit.  This would therefore support the view that a significant 
amount of time is wasted in the outpatient setting repeating these radiographs. The 
overall numbers of patients actually requiring such repeat radiographs remain, 
however relatively small (n= 56).  However, this may be due to the reluctance of 
specialist clinicians in subjecting patients to further radiation in repeating radiographs 
as WB. 
There is good evidence that tibio-femoral joint space narrowing is good evidence for 
cartilage loss [110]. In addition, our study confirms that a WB film significantly 
increases the amount of joint space narrowing, and hence the severity of 
osteoarthritis, when reported by a radiologist. This represents an area of possible 
delayed or missed diagnosis, with its potential costs in terms of complaints and/or 
litigation. 
From the results of our study, the numbers of patients who may be suffering from 
such a delay could potentially be quite large, with a pool of up to 1867 patients 
(those who had non-WB radiographs and did not have repeat WB radiographs) being 
under-diagnosed with regard to the extent of their knee osteoarthritis. This may then 
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result in delayed/inappropriate treatment or referral of such patients to specialist 
care. 
Our study raises the question whether a national policy to routinely perform elective 
knee radiographs with the patient WB should be implemented, or at the very least 
discussed between primary care institutions, radiology and orthopaedic departments.   
In the absence of such a national policy existing, our study suggests that it would be 
prudent for doctors in all specialities to request all AP and lateral knee radiographs 
as weight bearing (or “erect”) views, unless there is a history of trauma or the patient 
is not able to bear weight on the knee. 
Following the results of our study, our institution now routinely performs weight-
bearing x-rays on patients above the age of 40, when there is no history of trauma. 
 
7.6 Limitations of the Study and areas for future research 
A limitation of our study is that patients who had an initial radiograph at our institution 
but subsequently referred by their GP to another institution for their knee pathology 
would not be included in our results. Likewise, patients who have had their initial 
radiograph elsewhere and then subsequently referred to the orthopaedic department 
at our institution would similarly be excluded. However, we believe these numbers to 
be relatively small.    
In addition, the reporting radiologist was not blinded as to whether the radiographs 
were WB or non-WB, thus potentially biasing reporting. However we regard joint 
space loss as a significantly objective measure of degeneration for bias to have a 
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minimal influence.  Further studies on WB vs non-WB views should however involve 
reporting by a radiologist who is blinded to the manner in which the films were taken. 
Our study has investigated the direct costs of repeating radiographs in patients, but 
there also remain additional un-quantified indirect costs, which include, wasted 
clinical time - a service cost - to the clinicians and radiographers who might 
otherwise be able to use that time treating other patients. Other indirect costs include 
the potential of delayed or missed diagnosis of osteoarthritis, further unnecessary 
investigations ordered such as MRI, unnecessary radiation exposure to the patient 
and also causing, in general, a poorer patient experience, a subject of increasing 
relevance in these times. 
 
7.7 Conclusion: 
Only a small proportion of patients referred for knee radiographs by GPs have WB 
AP films. The radiographic features of osteoarthritis appear to be more severe on 
WB plain radiographs of the knee when compared with non-WB plain radiographs of 
the knee. In London, 46% of hospitals do not routinely perform WB radiographs to 
investigate suspected knee osteoarthritis, potentially leading to a delay in diagnosis, 
referral or treatment of these patients. It represents a significant risk and cost burden 
to the NHS. In the absence of a national policy on WB status on knee radiographs, 
we would recommend that knee radiographs be requested at “weight bearing” or 
“erect” when general practitioners complete the request form in cases that do not 
involve trauma. 
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Chapter 8 
Discussion, Further work and Conclusion 
8.1 Saving money in the knee replacement surgery 
The lack of detailed costing information regarding knee replacement surgery, in this 
day and age, is both frustrating and difficult to understand. This lack of information 
makes it difficult to determine a hospital’s financial position with regard to providing 
knee replacement surgery. Our TDABC study has shown that total knee 
replacement, as a treatment for osteoarthritis of the knee, is covered by the current 
tariff. Further savings are also possible, at a local level, in knee replacement surgery, 
through better understanding of the process and more robust accounting. By 
targeting the main cost drivers – implants and consumables being the highest - it is 
possible it is possible to come in well under the tariff, making a profit for the 
organisation.  
Greater awareness amongst surgeons regarding the cost implications of their choice 
of implants can further maximize any cost savings. Switching to a single provider 
service and selecting a lower cost but an equivalently performing implant (based on 
revision rates) would yield greater savings than, for example, attempting to further 
reduce length of stay. 
Corporate overheads remain a significant factor in the overall cost of knee 
replacement surgery. They also remain an arbitrary “black hole” for which costs are 
hidden, and therefore believed to be fixed and unalterable. It would require the 
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application of TDABC to all departments of the hospital and trust in order to convert 
these overheads into direct costs, which can then be properly allocated. Such work 
is beyond the scope of this thesis, but remains a worthwhile endeavour for further 
work in the future.  
 
8.2 Are Specialist orthopaedic units the way forward? 
The normal operating day runs from 0800 to 1700 in most NHS hospitals. Based on 
the timing data from our study, it would not be possible to perform more than 3 total 
knee replacements in a working day. Provisional data from the EOC suggests 
potentially greater efficiency based on the timings provided. However, a formal 
comparison of the two institutions through a prospective TDABC analysis would be 
required before firm conclusions can be drawn. 
There is evidence, based on NJR data, that specialist units have better clinical 
outcomes, both in terms of mortality and patient satisfaction [35]. However, the case 
still has to be made as to whether such units are more truly efficient in terms of cost. 
If the differential is significant, it may be an argument for routine elective joint 
replacement to cease at other types of institutions and for surgeons to come together 
at elective ‘cold’ units as suggested by Professor Briggs [88] . 
 
8.3 The nature of the firm 
The nature of the firm is an article by Ronald Coase in 2007  [111] which offers an 
explanation to why individuals seek to form companies and other corporate 
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organisations rather than trading through contracts on the market. Coase noted that 
the larger the firm: 
1. The less the costs of organisation, and the slower these costs rise. 
2. The less likely the entrepreneur is to make mistakes and the smaller the 
increase in mistakes with an increase in the transactions organised. 
3. The smaller the rise in supply price of factors of production to the firm. 
Such specialised orthopaedic units are therefore likely to have a number of benefits, 
including specialised orthopaedic theatre staff, lower implant costs from volume of 
sales, ring fenced elective orthopaedic beds, greater audit and clinical governance 
and potentially better rehabilitation services. These units may also have lower overall 
running costs and overheads if built, for example, away from central London. 
The counterargument against such specialised units, is that despite the very high 
overheads paid by our institution, the tertiary sub-specialty back-ups available are a 
considerable safety net when and if unforeseen complications occur. Such 
complications are more likely in complex revision surgery but can occur infrequently 
in primary knee replacement surgery. 
 
8.4 Future work with TDABC 
While the evidence may not yet be there, intuitively, the move towards more 
specialised orthopaedic units makes sense. While the evidence for cost savings still 
needs to be found, such units should be more efficient, by virtue of the specialisation 
for the reasons described above, and therefore, the direction of future research 
should be aimed towards this. 
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In the UK, knee replacement surgery is performed, on the NHS, in one of 3 classic 
institutional models – a District General hospital (DGH), a major Teaching hospital 
(often also a trauma centre) or a Specialised elective Orthopaedic hospital such as 
the EOC or the RNOH at Stanmore. 
A TDABC study could be performed at each of these 3 types of institutions to 
determine the comparative cost of knee replacements performed at each type of 
institution. The process maps for the TKR pathway utilised in our study are listed in 
Appendix 2. This can be used as a template or as comparison for the processes and 
costs for the 3 different institutions. 
On a larger scale, the work from TDABC study can be applied to allow comparisons 
between hospitals across different countries, allowing for more accurate international 
benchmarking. 
There has also been recent work looking at reducing costs through use of newer 
technologies – such as customized instrumentation or cutting blocks – in knee 
replacement surgery. Such efforts have been hampered by the lack of a robust 
costing methodology [60], calling into question the accuracy of the results and 
conclusions.  The process template from our study can also be utilised here, for 
future studies in this area in order to provide more robust data. 
 
8.5 Reducing future Litigation costs 
The rising litigation costs to the NHS – in both knee replacement surgery and more 
generally - has been highlighted in our study and others [35].  This rise of conditional 
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fee agreements (CFAs) or more commonly known as “no-win, no fee” agreements is 
often quoted in the media as a cause for the litigation increase [112].  
However, cases such Chester versus Afshar (2004) [113]- where the House of Lords 
decided that a doctor's failure to fully inform a patient of all surgery risks removes the 
need to show that harm would have been caused by the failure to inform- and more 
recently, the Supreme Court ruling in Montgomery v Lanarkshire Health Board 
(2015) [114] have also played a role by raising the standard of care due to patients. 
These cases have also set out in clearer terms, the responsibilities of doctors and 
surgeons on issues of consent, and thereby making it easier for claims to succeed.  
Our study utilising the NHSLA database has shown that technical errors have higher 
litigation success rates as compared to events less under the surgeon’s control. Our 
study has also highlighted the potential safety concerns regarding incorrectly sized 
prostheses. Such errors are arguably failures of experience, training or judgement, 
and hence potentially preventable.  As these represent the greater share of the 
litigation cost (being the more successful cases), preventing or reducing such 
occurrences would represent a significant cost saving for the NHS. 
The limited data available from the database, however, does not allow for more 
detailed conclusions to be drawn. Our work does highlight however, the need for 
further detailed research into this area to obtain the details of these technical errors, 
in order to provide lessons and guidelines for future prevention. As of 25th 
September 2015, the NHSLA has started sharing claims data with the Royal National 
Orthopaedic Hospital (RNOH) at Stanmore, as part of the GIRFT programme. The 
programme aims to drill down at the specific causes of these clinical negligence 
claims to identify poor practice, through detailed case analysis.  
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Despite its limitations, the NHSLA database remains one of the best sources for 
analysis of clinical negligence cases in the NHS. Clinical negligence cases brought 
by private patients, however, are not included in the database. For some areas of 
orthopaedic surgery, such as paediatrics or spine, the majority of the work is done on 
the NHS and as such the litigation cases from the NHSLA database represent a 
good reflection of claims in those specialties.  
To date, no orthopaedic study on clinical negligence has examined private litigation 
in England by use of a national database, such as those held by indemnity 
organisations such as the MDU or MPS. One study [115] has looked at private 
litigation against ENT surgeons utilising MDU data.   
As a significant amount of knee surgery is performed in the private sector and a 
future analysis of those claims would likely prove both valuable and insightful. 
Another potential area for future research would be investigating the effect of the 
WHO checklist on complications and/or litigation costs. 
 
8.6 Costs of X-rays and other imaging 
Our x-ray study identified cost savings, which while modest locally, represented a 
more substantial figure when applied nationally. The solution to obtain that cost 
savings involved a simple change of local policy, which occurred at our institution 
following the study.  
A significant number of patients are referred by their GP for MRI scans prior to 
referral to a specialist – either a physiotherapist or an orthopaedic surgeon. While 
MRI scans do not have the radiation implication of unnecessary x-rays, the volume 
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of such referrals puts potentially additional pressure on trusts to meet referral-to-
treatment times. Future work could examine the appropriateness and /or cost 
implications of such practice.  
 
8.7 The purchaser-provider split and the potential implications for
 future cost savings 
The work from this thesis has shown that there can be cost savings made in the 
treatment of osteoarthritis of the knee. The studies performed have highlighted areas 
where such savings can be made at a local level – whether through more modest 
savings such as reducing unnecessary imaging, or larger ones through better 
accounting and process management. In addition, the studies have shown areas on 
a national level – such as spiralling litigation costs- which also need addressing in 
order reduce costs both to the local hospital, and to the NHS as a whole. 
The NHS in England, however, is unique (unlike, for example the NHS in Wales or 
Ireland), in having a purchaser-provider system. Price-based competition was 
introduced into the NHS in 1991 under the Conservative Government of the day. 
There have been a number of reforms of this system, under the subsequent Labour 
administration and the current Conservative one, however, the internal market 
remains. 
As part of this thesis, I discussed with various managers at Imperial and elsewhere 
regarding the need to improve cost accounting, and developments such as the 
PLICS system. A number of managers expressed concern on the concept of greater 
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accuracy and transparency in costing. The concerns raised by those managers were 
that the goals of the purchaser and that of the provider were not necessarily aligned.  
While a hospital make seek to better gain control of its costs, the greater 
transparency resulting from reporting such costs could, in their opinion, drive down 
the tariff paid by the Commissioners. If the trust could do a knee replacement for 
£5422 then there was no incentive for the commissioners to pay any more than this.  
Hospitals and trusts have traditionally used the surplus produced by such 
procedures to compensate for areas where the tariff is insufficient to cover the cost 
for treatment, such as trauma. The loss of such income would therefore be 
disastrous. Hence, there was no incentive to improve the existing accounting 
practices, as reporting lower figures could result in reduced payments. 
On a higher governmental level, alignment of the goals and incentives to both the 
commissioners and hospital trusts is required to address this problem, so that 
efficient, well-performing hospitals are not subsequently penalised for their efficiency,  
 
8.8 Final Conclusion  
At a local level, TDABC represents a validated method for analysing and controlling 
costs. It is unfortunately highly time-consuming to use, and applying for all 
procedures, across all specialties in a hospital, would be, in my opinion, extremely 
unrealistic.   
It does however offer unparalleled transparency in determining where the major cost 
drivers for that procedure lie. In the current economic climate, this transparency 
would allow hospitals are over the tariff because of the complexity of their work or 
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the patient population that they serve, to be able to present the Commissioning 
Groups with a strong argument to renegotiate the tariff locally, to ensure that they 
are being paid fairly for the work.  
Accurate TDABC would allow hospital trusts to negotiate a better tariff for areas 
where it can be shown they are unfairly underpaid. Where the fault for being over-
tariff lies with the trust’s inefficiencies, it would allow identification of the relevant cost 
drivers, as in our study, so that appropriate actions can be taken to address them.  
Because of the impracticality of applying TDABC nationally, the development of 
PLICs software offers the opportunity for hospitals to collect patient level data, which 
can then be modelled at a national level. PLICs started in 2012/13 and at present 
however, the data remains un-validated. A possible future project could involve the 
use of TDABC to validate PLICs data. 
I would therefore argue strongly in favour using the TDABC system for all of an 
orthopaedic department’s “bread and butter” type procedures, such as total knee 
replacement, total hip replacement or knee arthroscopy.  
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APPENDIX 1: SLR Data from Imperial 
 
 
Cost Driver Cost Element Total Cost 
Consultant mins C4342319 £91.63 
Consultant mins C4342319 £91.63 
Consultant mins C4342319 £91.63 
Drug spend patient matched DVT038J £23.94 
Drug spend patient matched LACTULOSE (300mL) £1.41 
Drug spend patient matched OXYCODONE (OXYCONTIN) TABLETS MR 10mg £9.76 
Drug spend patient matched PARACETAMOL TABLETS 500MG (32) £0.37 
Drug spend patient matched SENNA TABLETS 7.5mg £1.22 
Imaging requests XKNEL £22.02 
Inpatient numers Trauma & Orthopaedics £0.29 
LOS Trauma & Orthopaedics £64.42 
LOS Trauma & Orthopaedics £16.67 
LOS Trauma & Orthopaedics £3.00 
LOS Trauma & Orthopaedics £15.33 
LOS Trauma & Orthopaedics £27.84 
LOS Trauma & Orthopaedics £0.28 
LOS Trauma & Orthopaedics £33.42 
LOS Trauma & Orthopaedics £2.73 
LOS Trauma & Orthopaedics £47.06 
LOS/attendances Trauma & Orthopaedics £329.77 
LOS/attendances Trauma & Orthopaedics £0.19 
LOS/attendances Trauma & Orthopaedics £1.15 
Path request Coagulation scr £9.44 
Path request FBC £5.62 
Path request Profile £4.30 
Patient numbers Trauma & Orthopaedics £15.62 
Patient numbers Trauma & Orthopaedics £7.92 
Patient numbers Trauma & Orthopaedics £45.66 
Patient numbers Trauma & Orthopaedics £4.72 
Patient numbers Trauma & Orthopaedics £3.69 
site wide patient numbers Trauma & Orthopaedics £0.13 
site wide patient numbers Trauma & Orthopaedics £0.87 
Surgeon Theatre mins CX02 £1,469.94 
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T&O Prosthesis averaged cost CX02 £2,133.02 
Theatre anaesthetic mins cx CX02 £836.11 
Theatre mins CX02 £25.22 
Theatre mins CX CX02 £174.65 
Theatre mins SPEC 110 CX02 £28.96 
Theatre numbers CX02 £118.14 
Theatre numbers CX02 £134.32 
Theatre numbers CX02 £32.45 
Theatre nursing mins CX CX02 £507.57 
Ward LOS RA7W £217.06 
Ward LOS RA7W £217.06 
Ward LOS RA7W £217.06 
Ward LOS RA7W £217.06 
Total   £7,302.35 
 
 
 
Cost Driver Cost Element Total Cost 
Blood RCLD £403.68 
Consultant mins MR D D M SPICER £91.63 
Consultant mins MR D D M SPICER £91.63 
Consultant mins MR D D M SPICER £91.63 
Consultant mins MR D D M SPICER £91.63 
Consultant mins MR D D M SPICER £91.63 
Consultant mins MR D D M SPICER £91.63 
Consultant mins MR D D M SPICER £91.63 
Consultant mins MR D D M SPICER £91.63 
Consultant mins MR D D M SPICER £91.63 
Drug spend patient matched LOSARTAN 100mg TABLETS £0.91 
Drug spend patient matched OMEPRAZOLE 20mg CAPSULES £1.14 
Drug spend patient matched PARACETAMOL TABLETS 500mg (100) £0.55 
Drug spend patient matched TRAMADOL CAPSULES 50mg (30) £1.19 
Imaging requests CAPUG £109.10 
Imaging requests XCHES £52.05 
Imaging requests XKNER £22.02 
Inpatient numers Trauma & Orthopaedics £0.29 
LOS Trauma & Orthopaedics £193.27 
LOS Trauma & Orthopaedics £50.02 
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LOS Trauma & Orthopaedics £8.98 
LOS Trauma & Orthopaedics £45.99 
LOS Trauma & Orthopaedics £83.52 
LOS Trauma & Orthopaedics £0.84 
LOS Trauma & Orthopaedics £100.25 
LOS Trauma & Orthopaedics £8.19 
LOS Trauma & Orthopaedics £141.19 
LOS/attendances Trauma & Orthopaedics £989.31 
LOS/attendances Trauma & Orthopaedics £0.58 
LOS/attendances Trauma & Orthopaedics £3.44 
Path request B-ABO £16.11 
Path request B-ABO £16.11 
Path request B-ABO £0.15 
Path request B-ABO £0.15 
Path request BIRXM £6.58 
Path request Blood Culture £17.25 
Path request Blood Culture £0.16 
Path request Coagulation scr £9.44 
Path request Coagulation scr £9.44 
Path request CReactive Prot £2.58 
Path request CReactive Prot £2.58 
Path request CReactive Prot £2.58 
Path request FBC £5.62 
Path request FBC £5.62 
Path request FBC £5.62 
Path request FBC £5.62 
Path request FBC £11.24 
Path request Manual Differen £17.06 
Path request Manual Differen £0.16 
Path request Profile £4.30 
Path request Profile £9.46 
Path request Profile £4.30 
Path request Profile £4.30 
Path request Profile £4.30 
Path request Troponin I £5.16 
Path request Urine Culture £8.14 
Patient numbers Trauma & Orthopaedics £46.87 
Patient numbers Trauma & Orthopaedics £23.75 
Patient numbers Trauma & Orthopaedics £136.98 
Patient numbers Trauma & Orthopaedics £14.16 
Patient numbers Trauma & Orthopaedics £11.07 
site wide patient numbers Trauma & Orthopaedics £0.13 
site wide patient numbers Trauma & Orthopaedics £0.87 
Surgeon Theatre mins CX03 £1,020.46 
T&O Prosthesis averaged cost, theatre mins CX03 £1,480.78 
Theatre anaesthetic mins cx CX03 £825.66 
Theatre mins CX03 £22.65 
Theatre mins CX CX03 £156.83 
Theatre mins SPEC 110 CX03 £26.00 
Theatre numbers CX03 £118.14 
Theatre numbers CX03 £134.32 
Theatre numbers CX03 £32.45 
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Theatre nursing mins CX CX03 £455.78 
Therapy mins Occupational Therapy Contact £62.31 
Therapy mins Occupational Therapy Contact £190.13 
Therapy mins Occupational Therapy Contact £71.90 
Ward LOS RA7W £217.06 
Ward LOS 
 
£434.13 
Ward LOS 
 
£217.06 
Ward LOS 
 
£217.06 
Ward LOS 
 
£217.06 
Ward LOS 
 
£217.06 
Ward LOS 
 
£217.06 
Ward LOS 
 
£217.06 
Ward LOS 
 
£217.06 
Ward LOS 
 
£217.06 
Ward LOS 
 
£217.06 
Total   £10,651.18 
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APPENDIX 2: Process Maps for ABC Pathway* 
The timings obtained for the following Process Maps were taken either directly (for 
the intra-operative pathway) by following the patient, or where this was not possible 
(such as in the outpatient, pre-operative, inpatient and follow-up pathways), these 
were obtained through interviews with the relevant staff to obtain accurate estimates. 
Process Steps: Outpatient Pathway 
Pathway 
reference 
number 
 
Stage 
 
Process Step 
 
Time 
(mins) 
 
Band or Grade 
1.1.2 Referral Undertake daily review/desktop triage of referrals to 
identify appropriate consultant 
0 7 
1.1.3 Referral Identify appointment slot within 5 days of receipt, 
Appointment 9-12 weeks from referral 
1 2 
1.1.5 Referral If necessary add patient to ICHIS 3 2 
1.1.6 Referral Generate a referral on ICHIS 1 2 
1.1.7 Referral Book patient into clinic 1 2 
1.1.9 Referral Send appointment letter to patient 1 2 
 Referral If there are appointment issues eg Urgent appointments 
some clinic slots may have to be rearranged 
10 7 
1.1.10 Referral Send referral letter to medical records 1 2 
1.1.11 Referral Review all new bookings on a weekly basis 1 5 
1.1.13 Referral Prepare patient notes prior to clinic 5 N/A 
1.1.13 Referral Prepare patient notes prior to clinic and check imaging is 
available in time for clinic 
5 2 
1.2.1 Clinic Patient arrives, log attendance on ICHIS 1 3 
1.2.2 Clinic Call patient into room, check details 1 5 
1.2.4 Clinic Complete x-ray request form and send patient to imaging 5 5 
1.2.5 Clinic Take x-ray send patient and results back to clinic 15 5 
1.2.6 Clinic Consultant makes an assessment through taking a medical 
history, examination and the imaging results 
15 Consultant 
1.2.9 Clinic Complete PPwT form, referral form and dictate letter back 
to GP 
5 Consultant 
1.2.10 Clinic Counsel patient, answer any relevant questions and hand 
them relevant literature 
15 5 
1.2.11 Clinic Write up dictation and send letter back to GP 30 3 
1.2.12 PPwT Collect PPwT and enter details into PPwT database, send 
information to NWT  
PPwT to obtain a unique reference number 
10 7 
1.2.13 PPwT Once unique reference number has been received, waiting 
list coordinator to confirm authorisation and patient can be 
listed 
10 7  
1.2.12 PPwT Collect PPwT forms and enter details into PPwT database, 
send information to NWT 
PPwTto obtain a unique reference number 
10 2 
1.2.13 PPwT Once unique reference number has been received, waiting 
list coordinator to confirm authorisation and patient can be 
listed 
10 2 
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Process Steps: Pre-operative 
Pathway 
reference 
number 
 
Stage 
 
Process Step 
 
Time 
(mins) 
 
Band or 
Grade 
1.3.1 Scheduling Receive referral from consultant, add patient to 
waiting list on ICHIS, book for pre-assessment and 
joint school.  Print off appointment letters and send 
out 
8 4 
1.3.17/1.3.10 Scheduling Find out why patient did not attend pre-assessment 
or joint school and rebook if required.  Also if 
anaesthetist not present during pre-assessment 
book appointment.  Print off appointment letters 
and sent out 
5 4 
1.3.15 Scheduling Book patients onto theatre lists for surgery.  Call 
patient and arrange a suitable date 
12 4 
 Scheduling Book equipment for each surgery, fill out form and 
send to theatre manager 
10 4 
 Scheduling Rebooking cancellations.  Reschedule the cancelled 
patients and call patients on list to fill slot 
30 4 
 Scheduling Review theatre list with consultant to ensure order 
and patient mix is correct 
5 4 
 Scheduling Review theatre list with consultant to ensure order 
and patient mix is correct 
5 Consultant 
 Scheduling Theatre man update, input the surgery list into 
Theatre Man a week before surgery 
5 4 
 Scheduling If patient is taken off waiting list eg because of 
repeat DNAs, medical reasons etc.  Have to send 
letter to GP and update ICHIS 
10 4 
1.3.2 Joint School Lead enhanced recovery nurse – introduction, 
overview of what happens during stay from a 
nursing point of view and Q&A session.  Only person 
to stay the entire session, time worked out per 
patient assuming 15 on average 
6 7 
1.3.2 Joint School Ward doctor explains the surgery, gives an overview 
of pain management and possible complications 
(Time / cost divided by 15 patients) 
2 SHO 
1.3.2 Joint School Occupational therapist gives an overview of what 
will be happening on every day after surgery and 
how to prepare for going home 
(Time / cost divided by 15 patients) 
1 5 
1.3.3 Preassessment 
– Nurse 
Take bloods, blood pressure, swabs complete 
integrated care plan (detailed medical history, 
medication etc) 
45 6 
 Preassessment 
– ECG 
Take ECG of patient 10 6 
1.3.4 Preassessment 
– OT 
Dialogue with the patient to understand their home 
environment, social situation and any other areas to 
be addressed 
20 5 
1.3.5 Preassessment 
– OT 
Write up the assessment and add to patient notes, 
generate an internal OT referral, highlight any social 
issues 
15 5 
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Process Steps: Intra-operative 
Pathway 
reference 
number 
 
Stage 
 
Process Step 
 
Time (mins) 
 
Band or Grade 
1.4.1 Surgery – 
Admission 
Patient arrives for surgery and is settled 
in/orientation completes consent form 
9 5 
1.4.2 Surgery – 
Anaesthetic 
Discuss anaesthetic options and make a decision 
with the patient on choice of anaesthesia 
7 Consultant 
1.4.3 Surgery - 
Consultnat 
See patient on morning of patient discuss 
procedure and sign consent form 
7 Consultant 
1.4.4 Surgery Sending time –send for the patient from surgery 
to porter leaving for patient 
6 2 
1.4.5 Surgery Portering time – transfer the patient from the 
ward up to theatre 
18 2 
1.4.6 Surgery Collection time- operating department 
practitioner (ODP) collects patient from theatre 
reception and brings through to theatre 
3 5 
1.4.6 Surgery Anaesthetic preparation time 9 Consultant` 
1.4.6 Surgery Anaesthetic preparation time 9 5 
1.4.6 Surgery Anaesthetic time – administer anaesthetic and 
prepare patient for theatre 
22 Consultant 
1.4.6 Surgery Anaesthetic time – administer anaesthetic and 
prepare patient for theatre 
22 5 
1.4.8 Surgery Scrub preparation time – this happens 
concurrently with the anaesthetic time, 
preparation of theatre for surgery, ensure 
enough sets have been uncovered etc 
30 6 
1.4.8 Surgery Scrub preparation time – this step happens 
concurrently with the anaesthetic time, 
preparation of theatre for surgery, ensure 
enough sets have been uncovered etc 
30 5 
1.4.6 Surgery Transition of patient into theatre by anaesthetist 
and ODP 
4 Consultant 
1.4.6 Surgery Transition of patient into theatre by anaesthetist 
and ODP 
4 5 
1.4.6/1.4.7 Surgery Position time – position patient correctly for 
surgery insert catherter, apply tourniquet, drape 
patient and hook patient up to ventilator 
21 Consultant 
1.4.6/1.4.7 Surgery Position time – position patient correctly for 
surgery insert catherter, apply tourniquet, drape 
patient and hook patient up to ventilator 
21 Consultant 
1.4.6/1.4.7 Surgery Position time – position patient correctly for 
surgery insert catherter, apply tourniquet, drape 
patient and hook patient up to ventilator 
21 SpR 
1.4.6/1.4.7 Surgery Position time – position patient correctly for 
surgery insert catherter, apply tourniquet, drape 
patient and hook patient up to ventilator 
21 5 
1.4.7 Surgery Surgical time – perform total knee replacement 98 Consultant 
(Anaesthetist)  
1.4.7 Surgery Surgical time – perform total knee replacement 98 Consultant 
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1.4.7 Surgery Surgical time – perform total knee replacement 98 SpR 
1.4.9/1.4.10 Surgery Surgical time – perform total knee replacement 98 6 
1.4.9/1.4.10 Surgery Surgical time – perform total knee replacement 98 5 
1.4.9/1.4.10 Surgery Surgical time – perform total knee replacement 98 5 
1.4.9/1.4.10 Surgery Surgical time – perform total knee replacement 98 5 
1.4.12 Surgery Transition patient through to recovery 9 Consultant 
1.4.12 Surgery Transition patient through to recovery 9 5 
1.4.11 Surgery Theatre clean up post surgery 13 6 
1.4.11 Surgery Theatre clean up post surgery 13 5 
1.4.11 Surgery Theatre clean up post surgery 13 5 
1.4.11 Surgery Theatre clean up post surgery 13 3 
1.4.12 Surgery Recovery time – patient waking up being 
attended to by a recovery nurse 
132 6 
1.4.13 Surgery Portering time – transfer the patient from the 
ward up to theatre 
18 2 
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Process Steps: Inpatient stay 
 
Pathway 
reference 
number 
 
Stage 
 
Process Step 
 
Time 
(mins) 
 
Band 
or 
Grade 
1.5.7 Ward stay Patient observations – assuming an average length of stay of 
5.25 days 
315 4 
1.5.7 Ward stay Prepare and administer medications 158 5 
1.5.7 Ward stay Cleaning wounds and changing dressings 105 5 
1.5.7 Ward stay First mobilisation out of bed 30 5 
1.5.7 Ward stay Taking bloods 15 2 
1.5.7 Ward stay Updating patient notes (30 mins per day) 158 6 
1.5.7 Ward stay Booking follow-up appointments 10 2 
1.5.7 Ward stay Post operative x-ray 15 N/A 
1.5.8 Ward stay Complete electronic discharge and request discharge 
medication if require 
10 SHO 
1.5.6 Ward stay Physiotherapist – basic function and movement, check chest, 
educate, teach exercises 
45 6 
1.5.6 Ward stay Physiotherapist – review exercises, progress with movement, 
walking with crutches 
158 6 
 Ward stay OT – ward assessment if required 30 5 
 Ward stay OT- if required complete social worker report 120 6 
 ERP Lead enhanced recovery nurse complete ERP report for the 
DOH 
10 7 
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Process Steps: Follow-up appointment outpatient clinic 
 
Pathway 
reference 
number 
 
Stage 
 
Process Step 
 
Time 
(mins) 
 
Band 
or 
Grade 
1.6.1 Follow-up Patient arrives log on ICHIS 1 3 
1.6.2 Follow-up Call patient into room, check details 12 5 
1.6.3/1.6.4 Follow-up Complete patient follow-up and dictate letter back to GP 13 SpR 
1.6.5 Follow-up Consultant secretary to check transcript and send letter 
(includes Dictate IT use) 
30 3 
 
 
 
 
Key: 
Step not performed for all patients  Step specific to CXH 
 Links to improvement opportunity 
 Step specific to SMH    Admin & Clerical step 
 
*This pathway map represents a collaborative project with Chris Cheyne of Ernst and 
Young. 
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APPENDIX 3: Pro-forma for X-ray reporting 
PROFORMA for Reporting X-rays 
DOB:                         Patient Initial:                    XR1:                 XR2:  
A ‘Normal’ X-ray: 1=not likely – 5=very likely 
1                              2                              3                              4                              5 
Please answer the following below questions as:  
1: None / 2: mild / 3: moderate / 4: severe / 5: very severe 
Presence of OA Grade – 
1                              2                              3                              4                              5 
 
Degenerative Change  
1                              2                              3                              4                              5 
 
Joint space reduction  
1                              2                              3                              4                              5 
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Osteophyte formation 
1                              2                              3                              4                              5 
 
Presence of sclerosis 
1                              2                              3                              4                              5 
 
Articular erosion  
1                              2                              3                              4                              5 
 
Radiological presence of effusion 
1                              2                              3                              4                              5 
 
Presence of loose bodies 
1                              2                              3                              4                              5 
 
Please answer the following below question as:  
1=not likely – 5=very likely 
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Likelihood of recommendation for orthopaedic referral: 
1                              2                              3                              4                              5 
 
 
 
 
 
 
 
